UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
   
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
OF
THE SECURITIES EXCHANGE ACT OFSecurities Exchange Act of 1934
   

Filed by the Registrantx 
Filed by a Party other than the Registranto

Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
x Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material Pursuant tounder §240.14a-12

LA JOLLA PHARMACEUTICAL COMPANY
(Name of Registrant as Specified Inin Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
xNo fee required.
oFee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 (1)Title of each class of securities to which transaction applies:
 (2)Aggregate number of securities to which transaction applies:
 (3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 (4)Proposed maximum aggregate value of transaction:
 (5)Total fee paid:
oFee paid previously with preliminary materials.
oCheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 (1)Amount Previously Paid:
 (2)Form, Schedule or Registration Statement No.:
 (3)Filing Party:
 (4)Date Filed:




image1a03.jpg
LA JOLLA PHARMACEUTICAL COMPANY
10182 Telesis Court, 6th Floor, San Diego, California 92121
   


image1a08.jpg
NOTICE OF THE 2020 ANNUAL MEETING OF SHAREHOLDERS
To Be Held On September 1, 2017TO BE HELD ON JUNE 25, 2020

To our Shareholders:the Shareholders of La Jolla Pharmaceutical Company:

You are cordially invited to attend the 2017The 2020 Annual Meeting of Shareholders (the “Annual Meeting”“Annual Meeting”) of La Jolla Pharmaceutical Company (the “Company”“Company”). The meeting will be held via live webcast at the La Jolla Beach and Tennis Club, located at 2000 Spindrift Drive, La Jolla, California,www.virtualshareholdermeeting.com/LJPC2020 on September 1, 2017June 25, 2020 at 9:00 a.m., local time. Pacific Time. The Annual Meeting will be held for the following purposes:purposes, as more fully described in the accompanying Definitive Proxy Statement (the “Proxy Statement”):
1.To elect up to five directorsthe 5 director nominees named in this Proxy Statement to serve until the Company’s 20182021 Annual Meeting of Shareholders;Shareholders and until their successors are duly elected and qualified;
2.To ratify the selection of Squar Milner LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017;2020; and
3.To approve an amendment to the Company’s 2013 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder; and
4.To transact any other businessmatters that may properly come before the meetingAnnual Meeting or any adjournmentadjournments or postponement of the meeting.postponements thereof.

The foregoing itemsAnnual Meeting will be a completely virtual meeting of business are more fully describedshareholders. You will not be able to attend the Annual Meeting in person. To participate, vote or submit questions during the proxy statement accompanying this notice.Annual Meeting via live webcast, please visit www.virtualshareholdermeeting.com/LJPC2020.

Only shareholders of record at the close of business on July 17, 2017, the record date of the Annual Meeting, will beApril 29, 2020 are entitled to notice of, and to vote aton, the Annual Meeting or any adjournment or postponement thereof. The Company’s Board of Directors has carefully reviewed and considered the foregoing Proposals and recommends that you vote FOR each nominee and each Proposalproposals described in the proxy statement. It is important that your shares be represented at the Annual Meeting, regardless of the size of your holdings. Accordingly, the Company urges you to vote promptly by completing, dating, signing and returning the enclosed proxy card in the enclosed postage-prepaid envelope, or by voting via telephone or the Internet as instructed in these materials. This will not limit your right to attend or vote at the Annual Meeting. You may revoke your proxy at any time before it has been voted at the meeting.Proxy Statement.

By the Order of the Board of Directors,

/s/ George F. TidmarshDennis Mulroy

George Tidmarsh, M.D., Ph.D.Dennis Mulroy
Chief ExecutiveFinancial Officer

San Diego, California
July 31, 2017April 29, 2020




Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to Be Held On September 1, 2017

The Proxy Statement and our 2016 Annual Report are available at www.proxyvote.com
   

YOUR VOTE IS IMPORTANTImportant Notice Regarding the Availability of Proxy Materials for the 2020 Annual Meeting of Shareholders to Be Held on June 25, 2020 at 9:00 a.m. Pacific Time via live webcast at www.virtualshareholdermeeting.com/LJPC2020.

Whether or not you expect to attendThe Proxy Statement and the Annual Meeting, youReport for the year ended December 31, 2019 are urged to mark, sign, date and return the enclosed proxy card as promptly as possible in the postage-prepaid envelope enclosed for that purpose or follow the instructions on the enclosed proxy card to vote via telephone or the Internet. Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, fiduciary or custodian, and you wish to voteavailable at the meeting, you must obtain a proxy card issued in your name from that intermediary. A majority of the outstanding shares of Common Stock entitled to vote at the Annual Meeting must be represented at the Annual Meeting, either in person or by proxy, to constitute a quorum.www.proxyvote.com.




image1a08.jpg
DEFINITIVE PROXY STATEMENT FOR
FOR THE 2020 ANNUAL MEETING OF SHAREHOLDERS
September 1, 2017June 25, 2020 at 9:00 a.m., local time Pacific Time
   

GENERAL INFORMATION

ThisYou are receiving these proxy statement is furnishedmaterials, including this Definitive Proxy Statement (this “Proxy Statement”), the Notice of the 2020 Annual Meeting of Shareholders, the 2019 Annual Report and the proxy card or voting instruction form, in connection with the solicitation of proxies by the Board of Directors (the “Board”“Board”) of La Jolla Pharmaceutical Company (the “Company(“we,” “us,” “our” or the “Company”) for use at the 2020 Annual Meeting of Shareholders to(the “Annual Meeting”). The Annual Meeting will be held via live webcast at www.virtualshareholdermeeting.com/LJPC2020on September 1, 2017,June 25, 2020 at 9:00 a.m., local time, Pacific Time, or at any other time following adjournments or postponements thereof (the “Annual Meeting”).thereof. The Annual Meeting will be held at the La Jolla Beach and Tennis Club, located at 2000 Spindrift Drive, La Jolla, California. This proxy statement, the related proxy, and Notice of Annual Meeting of Shareholders ismaterials are being mailed to our shareholders on or about July 31, 2017.May 6, 2020.

Only shareholders of record at the close of business on July 17, 2017April 29, 2020 (the “Record Date”“Record Date”) are entitled to notice of and to vote at the Annual Meeting.Meeting or any adjournment or postponement thereof. At the close of business on the Record Date, 22,123,45627,298,836 shares of common stock par value $0.0001 per share (the “Common Stock”), were issued and outstanding and held by 4 holders of record.outstanding. Each share of Common Stockcommon stock is entitled to one vote on each matter to be voted uponon at the Annual Meeting; shareholdersMeeting. Shareholders will not be entitled to cumulate votes in the election of directors. Shares cannot be voted at the Annual Meeting unless the holder thereof is represented, either by shareholders present via live webcast or represented by proxy. A majority of the outstanding shares of Common Stockcommon stock entitled to vote at the Annual Meeting must be represented at the Annual Meeting, either in personby shareholders present via live webcast or by proxy, to constitute a quorum.

Our Board has selected George F. Tidmarsh, M.D., Ph.D. and Dennis M. Mulroy to serve as proxiesproxy at the Annual Meeting. The shares of Common Stockcommon stock represented by each executed and returned proxy will be voted in accordance with the directionsinstructions indicated on the proxy card.card or voting instruction form.

If you are a shareholder of record and you sign your proxy card or voting instruction form without giving specific instructions, the Company will vote your shares “FOR” the Proposalseach director nominee and nominees set forth in this proxy statement.“FOR” Proposal 2. The proxy also confers discretionary authority to vote the shares authorizedentitled to be voted thereby on any matter that may properly may be presented for action atcome before the Annual Meeting; we currently know of no other business to be presented.

Any proxy given may be revoked by the person giving it at any time before it is voted at the Annual Meeting. If you have not voted through your broker, fiduciary or custodian, there are three ways fora shareholder of record, you tomay revoke your proxy and change your vote. First,vote through one of the following three ways: (i) you may send a written notice to the Company’s secretarySecretary, Dennis Mulroy, stating that you would like to revoke your proxy. Second,proxy; (ii) you may complete and submit a new proxy card, but it must bear a later date than the original proxy, or you may submit new proxy instructions via telephone or the Internet. Third,Internet; or (iii) you may vote in personvia live webcast at the Annual Meeting. However,Meeting, however, your attendance at the Annual Meeting will not, by itself, revoke your proxy. If you have instructed a broker, fiduciary or custodian to vote your shares, you must follow the directions you receive from your broker, fiduciary or custodian to revoke your proxy and change your vote. Your last vote will be the vote that is counted.

We will provide copies of this proxy statementProxy Statement and accompanyingthe related proxy materials to brokers, fiduciaries and custodians for forwarding to beneficial owners and will reimburse these persons for their costs of forwarding these materials. Our directors, officers and employees may solicit proxies by telephone, facsimile or personal solicitation. Wesolicitation; we will not pay additional compensation for any of these services.



QUESTIONS AND ANSWERS REGARDING
THIS SOLICITATIONABOUT THE PROXY MATERIALS AND VOTING AT THE ANNUAL MEETING

Q.Why am I receiving these proxy materials?


A.
You are receiving these proxy materials, from us because you were a shareholderincluding this Proxy Statement, the Notice of the 2020 Annual Meeting of Shareholders, the 2019 Annual Report and the proxy card or voting instruction form, in connection with the solicitation of proxies by the Board for use at the close of businessAnnual Meeting. The Annual Meeting will be held via live webcast at www.virtualshareholdermeeting.com/LJPC2020 on the Record Date. As a shareholder on the Record Date, youJune 25, 2020 at 9:00 a.m. Pacific Time, or at any other time following adjournments or postponements thereof. You are invited to attend the Annual Meeting and are entitled to, and requested to, vote on the items of businessproposals described in this Proxy Statement. The proxy statement.materials are being mailed to our shareholders on or about May 6, 2020.
Q.What is the format of the Annual Meeting?
A.We will be hosting the Annual Meeting via live webcast. You will not be able to attend the meeting in person. A summary of the information you need to attend the Annual Meeting online is provided below:

Any shareholder may listen to the Annual Meeting and participate via live webcast at www.virtualshareholdermeeting.com/LJPC2020. The webcast will begin at 9:00 a.m. Pacific Time on June 25, 2020.

Shareholders may vote and submit questions during the Annual Meeting via live webcast.

To join the Annual Meeting, please enter your 16-digit control number, which is available on your proxy card. If you do not have your 16-digit control number, you will only be able to listen to the Annual Meeting, and you will not be able to vote or submit questions live during the Annual Meeting.

Instructions on how to connect to and participate in the Annual Meeting via live webcast, including how to demonstrate proof of share ownership, will be posted at www.virtualshareholdermeeting.com/LJPC2020.
Q.How many shares must be present to conduct business?
A.A majority of the outstanding shares of Common Stockcommon stock entitled to vote at the Annual Meeting must be represented either at the Annual Meeting either in person or by proxy to constitute a quorum. A quorum is required to conduct business at the Annual Meeting.
Q.What will be voted on at the Annual Meeting?am I voting on?
A.The items of business scheduledproposals to be voted on at the Annual Meeting are as follows:
1.To elect up to five directorsElection of the 5 director nominees named in this Proxy Statement to serve until the Company’s 20182021 Annual Meeting of Shareholders;Shareholders and until their successors are duly elected and qualified;
2.
To ratifyRatification of the selection of Squar Milner LLP (“Squar Milner”) as the Company’s independent registered public accounting firm for the year ending December 31, 2017;
3.To approve an amendment to the Company’s 2013 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder; and
4.To transact any other business that may properly come before the meeting or any adjournment or postponement of the meeting.2020.
Q.How does the Board recommend that I vote?
A.The Board recommends that you vote your shares of common stock “FOR” each director nominee and in favor of the other Proposals presented herein.“FOR” Proposal 2.
Q.What shares can I vote at the Annual Meeting?
A.You may vote all shares of Common Stockcommon stock owned by you as of the Record Date, including: (1)(i) shares held directly in your name as the shareholder of record; and (2)(ii) shares held for you as the beneficial owner through a broker, fiduciary or custodian.
Q.What is the difference between holding shares as a shareholder of record and as a beneficial owner?
A.MostShareholder of our shareholders hold their sharesRecord: Shares of Common Stock through a broker, fiduciary or custodian rather than directlyRegistered in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.Your Name
Shareholders of Record.If your shares of common stock are registered directly in your name with our transfer agent, American Stock Transfer and& Trust Company, LLC, you are considered to be, with respect to those shares of common stock, the shareholder of record, and these proxy materials are being sent directly to you by us. As the shareholder of record, you have the right to vote in person at the Annual Meeting, vote by proxy using the enclosed proxy card or vote by proxy via telephone or the Internet. We have enclosed


Beneficial Owner: Shares of Common Stock Registered in the Name of a proxy card for you to use, which also contains instructions on how to vote via telephoneBroker, Fiduciary or the Internet.Custodian
Beneficial Owner.If your shares of common stock are held inby a brokerage accountbroker, fiduciary or by another nominee,custodian, you are considered the beneficial owner of shares of common stock held in street“street name,” and these proxy materials are being forwarded to you from that organization, together with a voting instruction form.broker, fiduciary or custodian. As the beneficial owner of shares of common stock held in “street name,” you have the right to direct your broker, fiduciary or custodian how to vote and are also invited to attend the Annual Meeting. Please note thatHowever, since a beneficial owner isyou are not the shareholder of record, you may not vote these shares in person at the Annual Meeting unless you obtain a “legal proxy” from the broker, fiduciary or custodian that holds your shares, giving you the right to vote the shares at the Annual Meeting. Your broker, fiduciary or custodian has enclosed or provided voting instructions for you to use in directing the broker, fiduciary or custodian how to vote your shares.


Q.How can I vote my shares without attending the Annual Meeting?
A.Whether you hold shares directly as theare a shareholder of record or beneficially in street name,a beneficial owner, you may direct how your shares are voted without attending the Annual Meeting. Shareholders of record of our Common Stock may vote by proxy using the enclosed proxy card or vote by proxy via telephone or the Internet. Shareholders who hold shares beneficially in street nameBeneficial owners may cause their shares to be voted by proxy using the proxy card or voting instruction form provided by their broker, fiduciary or custodian and mailing themit in the accompanying postage-prepaid envelope or vote via telephone or the Internet.
Q.How can I vote my shares in person at the Annual Meeting?
A.
Shares heldWe will be hosting the Annual Meeting via live webcast. You will not be able to attend the Annual Meeting in your name asperson. Any shareholder can listen to and participate in the shareholderAnnual Meeting via live webcast at www.virtualshareholdermeeting.com/LJPC2020. The webcast will start at 9:00 a.m. Pacific Time on June 25, 2020. For shareholders of record may be voted in person atto vote during the Annual Meeting. Shares held beneficially in street name may be voted in person only if youMeeting, follow the instructions posted at www.virtualshareholdermeeting.com/LJPC2020. Beneficial owners must obtain a “legal proxy”valid proxy from your broker, fiduciary or custodian. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, fiduciary or custodian that holds your shares giving you the right to vote the shares.request a proxy form. Even if you plan to attend the Annual Meeting, we recommend that you also submit your proxy card or voting instructions,instruction form, as described above, so that your vote will be counted if you later decide not to, or are unable to, attend the Annual Meeting.
Q.Is my vote confidential?
A.Proxy instructions, ballots and voting tabulations that identify individual shareholders are handled in a manner that protectsis designed to protect your voting privacy. Your vote will not be disclosed either within the Company or to third parties, except: (1)(i) as necessary to meet applicable legal requirements; (2)(ii) to allow for the tabulation of votes and the certification of the vote; and (3)(iii) to facilitate a successful proxy solicitation. Occasionally, shareholders provide written comments on their proxy card or voting instruction form, which may then be forwarded to the Company’s management.
Q.How are votes counted?
A.If you provide specific instructions with regard to an item, your shares will be voted as you instruct on such item. If you are a shareholder of record and sign your proxy card without giving specific instructions, your shares will be voted in accordance with the recommendations of the Board (“FOR” the director nominees identified herein, “FOR” ProposalsProposal 2 and 3, and in the discretion of the proxy holders on any other matters that properly come before the Annual Meeting).
Q.What is a “broker non-vote”?
A.A broker non-vote“broker non-vote” occurs when a beneficial owner of shares held in “street name” does not give instructions to the broker, fiduciary or custodian holding the shares as to how to vote on matters deemed “non-routine.” Generally, if shares of common stock are held in street“street name,” the beneficial owner of the shares is entitled to give voting instructions to the broker, fiduciary or custodian holding the shares. If the beneficial owner does not provide voting instructions, the broker, fiduciary or custodian can still vote the shares with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. Under the rules and interpretations of the New York Stock Exchange, “non-routine” matters are generally those involving a contest or a matter that may substantially affect the rights or privileges of shareholders, such as mergers, dissolutions or other shareholder proposals, as well as the election of directors and the approval of proposals relating to executive compensation and equity compensation plans. Because rulings on proposals are made pursuant to rules and interpretations governing the conduct of brokerage firms, rather than rules that apply directly to the Company, we have not made any determinations or predictions on how such rulings will be made. However, we have indicated below with respect to each proposal what the effect of a broker non-vote would be, if a non-vote is returned with respect to that proposal.


we have not made any determinations or predictions on how such rulings will be made. However, we have indicated below with respect to each proposal what the effect of a broker non-vote would be if a broker non-vote is returned with respect to that proposal. Broker non-votes will be counted as present for the purpose of determining the presence of a quorum.
Q. HowWhat is the vote required to approve each matter?
A.Proposal 1: Election of Directors
In an uncontested election (i.e., an election where the number of director nominees equals the number of director positions up for election), such as the one taking place at the Annual Meeting, directors are abstentions counted?elected by a majority of the votes cast, meaning each director nominee must receive a greater number of shares of common stock voted “FOR” his or her election than the number of shares of common stock voted “AGAINST” his or her election in order to be elected.
You may vote “FOR,” “AGAINST” or “ABSTAIN” for each of the director nominees. If you “ABSTAIN” from voting with respect to one or more director nominees, your vote will have no effect on the election of such nominees. In the election of directors, you may vote for no more than 5 director nominees, and you may not cumulate votes. Broker non-votes will have no effect on the election of the director nominees.
Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm
Ratification of the selection of the Company’s independent registered public accounting firm requires a “FOR” vote from a majority of shares of common stock present at the Annual Meeting, either represented by shareholders present via live webcast or by proxy, and entitled to vote on the proposal.
You may vote “FOR,” “AGAINST” or “ABSTAIN.” If you “ABSTAIN” from voting with respect to this proposal, your vote will have the same effect as a vote “AGAINST” the proposal. If this proposal is considered to be “routine,” there will not be any broker non-votes with respect to this proposal.
Q.What does it mean if I receive more than one set of proxy materials?
A.If you return a proxy card that indicates an abstention from voting on all matters, the shares represented will be counted as present for the purpose of determining the presence of a quorum, but they will not be voted on any matter at the Annual Meeting.
With regard to the election of directors, votes may be cast in favor of a director nominee or withheld. Because directors are elected by plurality, abstentions will be entirely excluded from the vote and will have no effect on its outcome.
With regard to Proposals 2 and 3, these matters require the approval of a majority of the votes cast on the matter affirmatively or negatively. Because abstentions are neither an affirmative nor negative vote, they will be disregarded. However, as noted above, approval of Proposals 2 and 3 also requires the affirmative vote of a majority of the shares necessary to constitute a quorum. As a result, a large number of abstentions could prevent the approval of these Proposals.


Q.What should I do if I receive more than one proxy?
A.You may receive more than one set of these proxy solicitation materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one broker, youof common stock may receive a separate voting instruction card for each brokerage account in which you hold shares. In addition, if you are a shareholder of record and your shares arebe registered in more than one name you may receive more than one proxy card.or held in different accounts. Please complete, sign, date and return each proxy card andor voting instruction cardform that you receive to ensure that all of your shares of common stock are voted.
Q.Who is soliciting my vote and who is paying the costs?
A.Your vote is being solicited on behalf of the Board, and the Company will pay the costs associated with the solicitation of proxies, including preparation, assembly, printing and mailing of this proxy statement.Proxy Statement.
Q.
How can I find out the results of the voting?voting results?
A.We intendexpect to announce preliminary voting results at the meeting and publish finalAnnual Meeting. Final voting results will be published in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (the “SEC”) within four4 business days followingafter the Annual Meeting.
Q.Whom should I contact if I have questions?
A.If you have any additional questions about the Annual Meeting or the Proposalsproposals presented in this proxy statement,Proxy Statement, you should contact:
Dennis M. Mulroy
Chief Financial Officer
La Jolla Pharmaceutical Company
10182 Telesis4550 Towne Centre Court 6th Floor
San Diego, CA 92121
(858) 433-6839207-4264 Ext: 1040



PROPOSAL 1: ELECTION OF DIRECTORS

Our Board of Directors

We currently have five5 members of our Board of Directors (the “Board”): George F. Tidmarsh, M.D., Ph.D.,Board: Kevin C. Tang, Craig Johnson, Laura L. Douglass, Craig A. Johnson, David Ramsay and Robert H. Rosen. All five5 of the incumbent directors have been nominated for reelection at the Annual Meeting. DirectorsDirector nominees elected at the Annual Meeting will hold office until the 20182021 Annual Meeting of Shareholders and in each case, until their successors are elected and qualified, unless they resign or their seats become vacant due to death, removal or other cause in accordance with our Articles of Incorporation.organizational documents. All of the director nominees have indicated their willingness to serve, if elected.

Unless authority to vote for any of the nominees is withheld in a proxy, shares represented by proxies will be voted FOR all nominees. In the event that any nominee for director becomes unavailable for reelection as a result of an unexpected occurrence, such shares will be voted for the election of such substitute nominee, if any, as the Board may propose. Alternatively, the Board may elect to reduce the size of the Board within the range authorized under the Articles of Incorporation.Director Nominees

The biographies of the director nominees and their ages as of July 1, 2017 are set forth below.

Nominees for Director

The peopleEach individual listed below areis nominated for election to the Board to serve a one-year term until his or her successor is elected and qualified following the 20182021 Annual Meeting of Shareholders. Our Board recommends that you vote FOR“FOR” each of the following director nominees:
Name Age Position
George F. Tidmarsh, M.D., Ph.D.57
President, Chief Executive Officer, Secretary and Director
Kevin C. Tang 5053
 Director, Chairman of the Board
Laura L. DouglassCraig Johnson 5358
 Director
Craig A.Laura Johnson 55
 Director
David Ramsay55
Director
Robert H. Rosen 6164
 Director

George F. Tidmarsh, M.D., Ph.D., has served as President, Chief Executive Officer, Secretary and a director of the Company since January 2012. Dr. Tidmarsh has more than 25 years of experience creating, building and leading biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. Prior to joining the Company, Dr. Tidmarsh was the Chief Executive Officer of Solana Therapeutics, Inc. from August 2011 to January 2012. In 2006, he founded Metronome Therapeutics, Inc., where he served as its Chief Executive Officer until its acquisition by Spectrum Pharmaceuticals, Inc. in 2010. In 2005, Dr. Tidmarsh founded Horizon Pharma, Inc., where he served as its President and Chief Executive Officer until 2008 and as a director and consultant until 2011. In 2001, he founded Threshold Pharmaceuticals, Inc., where he served as its President until 2005. Earlier in his career, Dr. Tidmarsh led the development of Doxil® (doxorubicin hydrochloride liposomal injection) while serving as Director of Oncology at Liposome Technology, Inc. Doxil has become a standard-of-care treatment for patients suffering from ovarian cancer. He serves as a director of the Citizens Oncology Foundation, a non-profit organization. Dr. Tidmarsh received his M.D. and Ph.D. from Stanford University, where he completed fellowship training in Pediatric Oncology and Neonatology and remains a Consulting Professor of Pediatrics and Neonatology. The Board has concluded that Dr. Tidmarsh should serve on our Board based on his extensive experience creating, building and leading biotechnology companies.

Kevin C. Tang has served as a director and as Chairman of the Board of the Company since August 2014. He serves as President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. Mr. Tang has more than 20 years of experience in evaluating, creating and building biotechnology companies that are focused on developing treatments for life-threatening and debilitating diseases and conditions. Mr. Tang isalso served as the Chairman and Chief Executive Officer of Odonate Therapeutics, LLC,Inc. since the company’s inception in 2013. Since 2009, he has served as a biopharmaceutical company dedicated to the developmentdirector of best-in-class therapeutics that improveHeron Therapeutics, Inc. and, extend the lives of patients with cancer.since 2012, has served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang also is the Presidentserved as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang Capital Management, LLC,was a life sciences-focused investment company he founded in 2002.director of Trimeris, Inc. From 1993 to 2001, Mr. Tanghe held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Since 2009, Mr. Tang has served as a director of Heron Therapeutics, Inc. and, since 2012, has served as the Chairman of its Board of Directors. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc.


and served as a director from its inception through its acquisition by AstraZeneca PLC in 2012. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. From 2001 to 2008, Mr. Tang was a director of Trimeris, Inc. (acquired by Synageva Biopharma Corp.). Mr. Tang received a B.S. degree from Duke University. The Board has concluded that Mr. Tang should serve on our Boardas a director based on his extensive experience forming and building biotechnology companies, serving as a director of numerous biotechnology companies and serving as a manager of funds specializing in the area of life sciences.

Laura L. Douglass has served as a director of the Company since October 2013. Ms. Douglass has more than 25 years of operating experience in the drug development industry with a particular expertise in clinical trial design and execution. Ms. Douglass is currently the President and Chief Executive Officer of Next Generation Clinical Research, a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Douglass serves as the President and Chief Executive Officer for Eufaeria Biosciences, Inc. Ms. Douglass is also a founder and director of SB Bancorp, Inc. and Settlers Bank, Inc. She also serves as a director of Agrace HospiceCare. Ms. Douglass received a nursing degree from The University of the State of New York-Albany. The Board has concluded that Ms. Douglass should serve on our Board based on her substantial operating experience and expertise in clinical trial management.

Craig A. Johnson has served as a director of the Company since October 2013. Mr. Johnson has more than 25 years of experience serving in senior financial management roles and governing corporations, primarily in the biotechnology industry. Mr. Johnson is currentlyHe also serves as a director of MiratiHeron Therapeutics, Inc., HeronMirati Therapeutics, Inc. and GenomeDx Biosciences,Odonate Therapeutics, Inc. Mr. Johnson served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018. He served as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014 and as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012, and as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014.2012. From 2011 to 2012, he wasMr. Johnson served as Chief Financial Officer of PURE Bioscience, Inc. From, and, from 2010 to 2011, he wasserved as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc., and, from 2004 until its acquisition by Raptor Pharmaceutical Corp. in 2009 and thento 2010, as Vice President of a wholly-ownedwholly owned subsidiary of Raptor from 2009Pharmaceuticals Corp. From 1994 to 2010. He2004, he held severalvarious positions includingat MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994,Operations. Mr. Johnson held senior financial positions with several early-stage technology companies and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. JohnsonWaterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn. The Board has concluded that Mr. Johnson should serve on our Boardas a director based on his substantial experience governingserving as a director of biotechnology companies and his expertise in financial management.

Laura Johnson has served as a director since October 2013. She is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Johnson is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Since 2018, she has served as a director of Odonate Therapeutics, Inc. Ms. Johnson is also a founder and director of SB Bancorp, Inc.


and Settlers Bank, Inc. Ms. Johnson received a nursing degree from the University of the State of New York-Albany. The Board has concluded that Ms. Johnson should serve as a director based on her substantial operating experience and expertise in clinical study management.

David Ramsay has served as a director since September 2019. Since 2011, he has served as a director of Savara, Inc. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. From 2003 to 2015, he held various positions at Halozyme Therapeutics, Inc., most recently serving as Chief Financial Officer. From 2000 to 2003, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc. From 1998 to 2000, he served as Vice President, Treasurer and Director, Corporate Finance at Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.). Mr. Ramsay began his career at Deloitte & Touche LLP. Mr. Ramsay received a B.S. in business administration from the University of California, Berkeley, an MBA in finance and strategic management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California. The Board has concluded that Mr. Ramsay should serve as a director based on his experience serving as a director of biotechnology companies and his expertise in financial management.

Robert H. Rosen has served as a director of the Company since July 2014. Since 2017, he has served as a director of Odonate Therapeutics, Inc. From 2013 to 2019, Mr. Rosen has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing innovative pharmaceutical products. Mr. Rosen has served as President and as a director of Heron Therapeutics, Inc. since May 2013. Prior, and, from 2012 to his appointment as President of Heron Therapeutics, he2013, served as Senior Vice President and Chief Commercial Officer beginning in October 2012. Priorof Heron Therapeutics, Inc. From 2014 to joining Heron Therapeutics,2015, he served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From April 2011 to March 2012, Mr. Rosenhe served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, heMr. Rosen served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan and Asia Pacific. During his tenure at Bayer, Mr. Rosen led the launch of Nexavar® (sorafenib) for the treatment of renal cell carcinoma and hepatocellular carcinoma.Pharmaceuticals. From 2002 to 2005, Mr. Rosenhe was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc., where he was responsible for the development of Sanofi’s U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. From November 2014 to December 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). Mr. Rosen received a B.S. degree in pharmacy from Northeastern University. The Board has concluded that Mr. Rosen should serve on our Boardas a director based on his extensive leadership experience in the biotechnology and pharmaceutical industryindustries and expertise in commercializing innovative pharmaceutical products.

Vote RequiredBoard Recommendation

The five director nominees who receive the greatest number of affirmative votes of the shares present in person or by proxy will be elected as directors. Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the election of directors. Proxies solicited by the Board will be voted for all nominees unless you specify otherwise in your proxy.

We strongly encourage you to submit your voting instruction card and exercise your right to vote as a shareholder.



Recommendation of the Board of Directors

The Board of Directors unanimously recommends that youa vote “FOR” each of the director nominees identified above.



PROPOSAL 2: RATIFICATION OF SELECTION OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Our BoardAudit Committee has selected Squar Milner LLP (“as the Company’s independent registered accounting firm for the year ending December 31, 2020. At the Annual Meeting, the shareholders will vote to ratify the selection of Squar Milner”) to serve LLP as ourthe Company’s independent registered public accounting firm for the year ending December 31, 2017.2020. Representatives of Squar Milner has served as our independent registered public accounting firm since January 2013LLP are expected to be present at the Annual Meeting. They will have the opportunity to make a statement, if they desire to do so, and commenced auditing our financial statements for the year ended December 31, 2012.will be available to respond to appropriate questions.

TheShareholder ratification of the selection of ourSquar Milner LLP as the Company’s independent registered public accounting firm is not required to be submitted for shareholder approval. Nonetheless,by law or our Bylaws. However, our Audit Committee is submitting the Board is seeking ratification of its selection of Squar Milner LLP to the shareholders for ratification as a matter of good corporate governance.practice. If our shareholders fail to ratify the shareholders do not ratify this selection, the Boardour Audit Committee will reconsider its selection of Squar Milner and will either continue to retain the firm or appoint a new independent registered public accounting firm.selection. Even if the selection is ratified, the Board may,our Audit Committee, in its sole discretion, determine to appointmay direct the selection of a different independent registered public accounting firm at any time during the year if it determinesthey determine that such a change would be in ourthe best interests of the Company and our shareholders’ best interests.

Representatives of Squar Milner are expected to be present at the Annual Meeting, and they will be given an opportunity to make a statement if they desire to do so and are expected to be available to respond to any appropriate questions from shareholders.

Independent Registered Public Accounting Firm and Fees

The following table presents therepresents aggregate fees for services provided by Squar Milner LLP duringfor each of the fiscal years ended December 31, 2016 and 2015:periods below:
2016 20152019 2018
Audit Fees$141,068
 $177,656
$183,798
 $175,191
Audit-Related Fees10,260
 31,402
Audit-related Fees18,684
 20,088
Tax Fees13,083
 7,910
—
 —
All Other Fees—
 —
Total$164,411
 $216,968
$202,482
 $195,279

Audit Fees. TheAudit fees identified under this caption wereconsists of fees for professional services renderedprovided by Squar Milner forLLP for: (1) the annual audit of our consolidated financial statements and internal control over financial reporting. The fees identified under this caption also include fees for professional services rendered by Squar Milner forreporting included in our Annual Report on Form 10-K; and (2) the reviewreviews of theour unaudited condensed consolidated financial statements included in our quarterly reports on Form 10-Q.

Audit-RelatedAudit-related Fees. Audit relatedAudit-related fees consist of fees paid tofor professional services rendered by Squar Milner LLP in connection with their consents on the Company’s registration statementsour Registration Statements on Forms S-3 and S-8.S-8 and the audit of our 401(k) plan.

Tax Fees.  Tax fees consist principally of assistance related to tax compliance and reporting.

Pre-approval Policy.  Our Audit Committee approves in advance all services provided by our independent registered public accounting firm. All engagements of our independent registered public accounting firm for 20162019 and 20152018 were pre-approved by the Audit Committee.

Vote RequiredBoard Recommendation

The approval of a majority of the votes cast affirmatively or negatively is required to approve this Proposal. Further, approval of this Proposal also requires the affirmative vote of a majority of the shares necessary to constitute a quorum for the Annual Meeting. As a result, broker non-votes and abstentions will be disregarded in determining whether the affirmative votes cast represent a majority of the total number of votes cast on this Proposal (the so-called “majority-of-the-quorum” requirement). However, a large number of abstentions or broker non-votes could prevent approval of this Proposal under the majority-of-the-quorum requirement.

Recommendation of the Board of Directors

The Board of Directors unanimously recommends that youa vote “FOR” the ratification of the selection of Squar Milner LLP as the Company’s independent registered public accounting firm.



PROPOSAL 3: AMENDMENT TO THE COMPANY’S 2013 EQUITY INCENTIVE PLAN

The current total share reserve underfirm for the Company’s 2013 Equity Incentive Plan (the “2013 Plan”) is 4,600,000 shares of Common Stock. As of July 1, 2017, equity awards covering a total of 3,838,115 shares were outstanding, and 558,992 shares remained available for new grants under the 2013 Plan.

We use the 2013 Plan to provide meaningful equity incentives to recruit, retain and reward qualified employees, consultants and directors of appropriate experience and stature. By increasing stock ownership, we aim to align the interests of qualified employees, consultants and directors with the interests of our shareholders. Our Board has unanimously approved, subject to shareholder approval, an amendment to the 2013 Plan to increase the number of shares authorized for issuance thereunder to a total of 8,100,000 shares, representing an increase of 3,500,000 shares. If this Proposal is approved, the text of Section 4(a) of the 2013 Plan, which sets forth the authorized share reserve under the plan, will be amended and restated to read as follows:

4. LIMITS ON AWARDS UNDER THE PLAN

(a)Number of Shares. The maximum number of shares of Stock that may be delivered upon satisfaction of Awards under the Plan shall be 8,100,000 shares of Stock (the “Reserve”). The limits set forth in this Section 4(a) shall be construed to comply with Section 422. Without limiting the generality of the foregoing, no more than 8,100,000 shares of Stock may be issued in satisfaction of the exercise or surrender of ISOs granted under the Plan. To the extent consistent with the requirements of Section 422 and with other applicable legal requirements (including applicable stock exchange requirements), Stock issued under awards of an acquired company that are converted, replaced, or adjusted in connection with the acquisition shall not reduce the number of shares available for Awards under the Plan.

Existing Equity Plan Information

The following table includes aggregated information regarding awards outstanding under our 2013 Plan, the number of shares available for future awards under our 2013 Plan as of July 1, 2017, and the proposed number of shares issuable under the 2013 Plan:
 
Number
of shares
 
As a percentage of
stock outstanding(1)
Outstanding stock options3,838,115
 11.41%
Outstanding restricted stock awards and exercised options202,893
 0.60%
Total shares issued or subject to outstanding awards as of July 1, 20174,041,008
 12.01%
Total shares available for future awards as of July 1, 2017558,992
 1.66%
Proposed increase in shares available for future awards3,500,000
 10.41%
Proposed shares available for future awards4,058,992
 12.07%

1.Percentage outstanding is calculated on an as-converted, fully diluted basis, which includes the Common Stock underlying our issued and outstanding convertible preferred stock and options to purchase Common Stock.

The maximum term for stock options under the 2013 Plan is ten years and the weighted-average remaining term of outstanding stock options is approximately 8.6 years. Certain additional information with respect to all of our equity compensation plans in effect as ofyear ending December 31, 2016 is provided under the heading “Equity Compensation Plan Information.”

The potential dilution from the 3,500,000 share increase requested is approximately 10.41% (calculated as the additional shares requested, divided by the as-converted, fully-diluted shares outstanding as of the Record Date). If the potential share request is approved, the Company's total potential dilution from the shares available for issuance under the 2013 Plan would increase from 1.66% (calculated as the total shares available for future awards under the 2013 Plan as of the Record Date, divided by the as-converted, fully-diluted shares outstanding as of the Record Date) to 12.07% (calculated as the quotient of: (a) the sum of: (i) the shares available for future awards under the 2013 Plan as of the Record Date; plus (ii) the 3,500,000 requested share increase; divided by (b) the as-converted, fully-diluted shares outstanding as of the Record Date). The Board has considered this potential dilution level and believes that the resulting dilution levels would be within normal ranges for similarly situated biotechnology companies.



In addition to overall dilution, in recommending the size of the increase in the share reserve under the 2013 Plan, the Compensation Committee considered annual dilution from the Company’s equity incentive plans. The Company measures annual dilution as the total number of shares subject to equity awards granted during the year, less cancellations and other shares returned to the reserve, divided by total common shares and common share equivalents outstanding at the end of the year. The Company’s annual dilution under the 2013 Plan for 2016 calculated on this basis was approximately 5.5%.

The Company manages its long-term dilution goal by limiting the number of shares subject to equity awards that it grants annually, commonly referred to as burn rate. Burn rate is defined as the number of shares granted under the Company’s equity incentive plans, less cancellations and other shares returned to the reserve, divided by the average number of shares of Common Stock and common share equivalents outstanding during the year. The Company has calculated the annualized burn rate under the 2013 Plan for the past three years, as set forth in the following table:
 
Options
Granted
 
Full-Value
Shares Granted
 
Total
Granted
 
Average
Number of Fully
 Diluted Shares
 
Annualized
Burn Rate
2014 - 20164,064,000 7,000 4,071,000 24,943,000 5.44%

An additional metric that the Company uses to measure the cumulative impact of its equity incentive programs is overhang. Overhang equals the quotient of: (a) the sum of: (1) the number of shares subject to equity awards outstanding but not exercised or settled, plus (2) the number of shares available to be granted under the equity plans; divided by (b) the sum of: (1) the total number of as-converted, fully-diluted shares outstanding as of the Record Date, plus (2) the number of shares available to be granted under the equity plans. If the proposed amendment to the 2013 Plan is approved, the Company’s overhang calculated on this basis would increase to approximately 21% and then would be expected to decline as awards are exercised and/or become vested.

Reasons for Seeking Shareholder Approval

The Board believes that equity-based compensation is a critical part of the Company’s compensation program. Shareholder approval of the amendment to increase the shares available under the 2013 Plan would allow us to continue to attract and retain directors, executives, other employees and consultants with equity incentives. The Company granted an average of 1,721,000 equity awards per year under its existing equity incentive plans during 2015 and 2016. The Company estimates that the availability of 3,500,000 additional shares for future awards would provide a sufficient number of shares to enable the Company to continue to make awards for the next one to two years, depending on the size of the commercial team expected to be hired, our clinical development programs, other related personnel growth and the amount, timing and financial terms of fundraising activity, which may impact the timing and degree of overall dilution.

General Provisions of the 2013 Plan

The following is a summary of the principal features of the 2013 Plan. The summary below is qualified in its entirety by the terms of the 2013 Plan, as proposed to be amended, a copy of which is attached hereto as Appendix A and is incorporated by reference herein.2020.

Purpose. The purpose of the 2013 Plan is to advance our and our shareholders’ interests by providing eligible persons with financial incentives to promote the success of our business objectives, by increasing eligible persons’ proprietary interest in us and by giving us a means to attract and retain employees, directors and consultants of appropriate experience and stature.

Administration, Amendment and Termination. The 2013 Plan will be administered by the Board (the “Administrator”), except that the Board may delegate: (i) to one or more of its members such of its duties, powers and responsibilities as it may determine; and (ii) to such employees or other persons as it determines such ministerial tasks as it deems appropriate. In the event of any delegation described in the preceding sentence, the term “Administrator” includes the person or persons so delegated to the extent of such delegation. The Administrator has the authority to: (i) interpret the 2013 Plan; (ii) determine eligibility for and grant awards under the 2013 Plan; (iii) determine, modify or waive the terms and conditions of any award granted under the 2013 Plan; (iv) prescribe forms, rules and procedures; and (v) otherwise do all things necessary to carry out the purposes of the 2013 Plan.

The Administrator, in its discretion, selects from the class of eligible persons those individuals to whom awards will be granted and determines the nature, dates, amounts, exercise prices, vesting periods and other relevant terms of such awards. The Administrator may modify the terms and conditions of an award, which requires the consent of the recipient of such award


if the modification will adversely affect the recipient’s rights under the award. However, outstanding options may not be re-priced without shareholder approval. All determinations of the Administrator are conclusive and binding on all parties.

Eligibility. The Administrator will select participants from among those key employees and directors of, and consultants and advisors to, the Company or its affiliates who, in the opinion of the Administrator, are in a position to make a significant contribution to the success of the Company and its affiliates; provided, that, subject to such express exceptions, if any, as the Administrator may establish, eligibility may be further limited to those persons as to whom the use of a Form S-8 registration statement is permissible. Currently, there are approximately seventy-seven employees and four non-employee directors of the Company who are eligible to participate in the 2013 Plan. Eligibility for ISOs (as defined below) is limited to employees of the Company or of a “parent corporation” or “subsidiary corporation” of the Company as those terms are defined in Section 424 of the U.S. Internal Revenue Code of 1986, as in effect and amended from time to time, or any successor statute in effect (the “Internal Revenue Code”).

Securities Subject to the 2013 Plan. The number of shares of our Common Stock that could be issued and outstanding or subject to outstanding awards granted under the 2013 Plan is currently set at 4,600,000 shares. If this Proposal is approved, the share reserve will be fixed at 8,100,000 shares. To the extent consistent with applicable legal requirements, shares of Common Stock issued under awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition will not reduce the number of shares available for awards under the 2013 Plan. The shares to be issued under the 2013 Plan will be made available either from authorized but unissued shares of our Common Stock or from previously issued shares of our Common Stock that we reacquire, including shares purchased on the open market.

Adjustments. The number and kind of shares of Common Stock or other securities available under the 2013 Plan in general, as well as the number and kind of shares of Common Stock or other securities subject to outstanding awards and the price per share of such awards, may be proportionately adjusted to reflect stock splits, stock dividends and other capital stock transactions.

Section 162(m) of the Internal Revenue Code Limitations. In general, Section 162(m) of the Internal Revenue Code imposes a $1 million limit on the amount of compensation that we may deduct in any tax year with respect to our Chief Executive Officer and each of our other three most highly compensated officers (excluding a Chief Financial Officer), including any compensation relating to an award granted under the 2013 Plan. The 2013 Plan is designed to allow us to grant awards that are not subject to the $1 million limit imposed by Section 162(m). However, the rules promulgated under Section 162(m) are complicated, and may change from time to time, sometimes with retroactive effect. As such, it cannot be guaranteed that any amounts intended to qualify as “performance based compensation” under Section 162(m) will so qualify. The maximum number of shares subject to awards that may be granted to any person in any calendar year and the maximum number of shares of stock subject to SARs (as defined further below) granted to any person in any calendar year will each be equal to 500,000 shares. The maximum amount payable to any person in any year under cash awards will be $250,000. Furthermore, if Section 162(m) would otherwise apply and if the amount of compensation a person would receive under an award is not based solely upon an increase in the value of the underlying shares of our Common Stock after the date of grant or award, the Administrator is authorized to condition the grant, vesting, or exercisability of such an award on the attainment of a pre-established objective performance goal. The 2013 Plan defines a pre-established objective performance goal to include one or more of the following performance criteria: (measured either absolutely or by reference to an index or indices and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof) sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; shareholder return; operating or gross margin; operating income; net income (before or after taxes); net operating income; net operating income after tax; pre- and after-tax income; pre-tax profit; cash flow, determined in the aggregate (or on a per share basis); operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of expense or working capital levels; economic value added (or an equivalent metric); debt reduction; implementation or completion of projects or processes; sales of particular products or services; customer acquisition, retention or satisfaction; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings. To the extent consistent with the requirements for satisfying the performance-based compensation exception under Section 162(m), the Administrator may provide in the case of any award intended to qualify for such exception that one or more of the performance criteria applicable to such award will be adjusted in an objectively determinable manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable performance criterion or criteria.



Non-Assignability of Awards. Awards are generally not transferable by a recipient during the life of the recipient. Awards are generally exercisable during the life of a recipient only by the recipient.

Shareholder Rights. No recipient or permitted transferee of an award under the 2013 Plan will have any rights as a shareholder with respect to any shares issuable or issued in connection with the award until we receive all amounts payable in connection with exercise of the award and performance by the recipient of all obligations under such award.

Award Types

Stock Options. Stock options granted under the 2013 Plan may be incentive stock options (“ISOs”), which are intended to qualify under the provisions of Section 422 of the Internal Revenue Code, or nonqualified stock options (“NSOs”), which do not so qualify.

The exercise price (or the base value from which appreciation is to be measured) of each award requiring exercise will be 100% (in the case of an ISO granted to a ten-percent shareholder, within the meaning of subsection (b)(6) of Section 422, 110%) of the fair market value of the stock subject to the award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant. To the extent the Company has a class of securities listed for trading on the Nasdaq Capital Market, no award, once granted, may be re-priced other than in accordance with the applicable shareholder approval requirements of the Nasdaq Capital Market. Fair market value will be determined by the Administrator consistent with the applicable requirements of Section 422 and Section 409A.

Where the exercise of an award is to be accompanied by payment, payment of the exercise price will be by cash or check acceptable to the Administrator, or, if so permitted by the Administrator and if legally permissible: (i) through the delivery of unrestricted shares of stock that have a fair market value equal to the exercise price, subject to such minimum holding period requirements, if any, as the Administrator may prescribe; (ii) through a broker-assisted exercise program acceptable to the Administrator; (iii) by other means acceptable to the Administrator; or (iv) by any combination of the foregoing permissible forms of payment. The delivery of shares in payment of the exercise price under clause (i) above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe.

Options granted under the 2013 Plan vest, become exercisable and terminate as determined by the Administrator. All options granted under the 2013 Plan may be exercised at any time after they vest and before their expiration date or earlier termination; provided that no option may be exercised more than 10 years after the date of its grant; and provided further that the exercise period may be less than 10 years if required by the Internal Revenue Code. In the absence of a specific written agreement to the contrary, and in each case subject to earlier termination on the option’s original expiration date, options will generally terminate: three months after termination of the recipient’s employment with us; 12 months after death; and, immediately with respect to termination of employment for reasons which cause discredit on the participant as to justify immediate termination. Notwithstanding the foregoing, however, the Administrator may designate shorter or longer periods after termination of employment to exercise any option if provided for in the instrument evidencing the grant of the options or if agreed upon in writing by the recipient. Options cease to vest upon termination of employment, but the Administrator may accelerate the vesting of any or all options that had not become exercisable on or prior to the date of such termination.

Other Awards. In addition to options, the Administrator may also grant performance awards, restricted stock, stock appreciation rights (“SARs”), unrestricted stock, stock units, including restricted stock units, and other awards that are convertible into or otherwise based on stock. Performance awards entitle the recipient to a payment in cash or shares of our Common Stock upon the satisfaction of certain performance criteria. Shares of restricted stock may be granted by the Administrator to recipients who may not transfer the restricted shares until the restrictions are removed or expire. The Administrator may also approve stock payments of our Common Stock to any eligible person and may also grant Common Stock or other awards to recipients of options, SARs or other awards denominated in shares of Common Stock. For all such awards, the Administrator will generally determine the relevant criteria, terms and restrictions.

Certain Material U.S. Federal Income Tax Considerations

The following summary of certain federal income tax considerations with respect to the receipt and exercise of awards granted by us is based upon federal income tax rules in effect as of the date of this proxy statement and does not purport to be a complete statement of the law in this area. Furthermore, the discussion below does not address the tax considerations regarding the receipt and exercise of awards under foreign, state and local tax laws, and such tax laws may not correspond to the federal income tax treatment described herein. The exact federal income tax treatment of transactions under the 2013 Plan will vary depending upon the specific facts and circumstances involved and participants are advised to consult their personal tax advisors


with regard to all considerations arising with respect to the grant or exercise of awards and the disposition of any acquired shares.

Incentive Stock Options. The 2013 Plan provides for the grant of stock options that qualify as ISOs as defined in Section 422 of the Internal Revenue Code. Except as discussed below, a recipient of an ISO generally is not subject to ordinary income tax on the grant or the exercise of an ISO if the recipient exercises the option while the recipient is our employee (or an employee of any parent or subsidiary corporation) or within three months following termination of the recipient’s employment (or within one year, if termination was due to a permanent and total disability).

If the recipient of the ISO sells the shares acquired upon the exercise of the option at any time within one year after the date we issue such shares to the recipient or within two years after the date we grant the ISO to the recipient (a “disqualifying disposition”), then:
if the recipient’s sales price exceeds the purchase price paid for the shares upon exercise of the ISO, the recipient will recognize capital gain equal to the excess, if any, of the sales price over the fair market value of the shares on the date of exercise, and will recognize ordinary income equal to the excess, if any, of the lesser of the sales price or the fair market value of the shares on the date of exercise over the purchase price paid for the shares upon exercise of the ISO; or
if the recipient’s sales price is less than the purchase price paid for the shares upon exercise of the ISO, the recipient will recognize a capital loss equal to the excess of the purchase price paid for the shares upon exercise of the ISO over the sales price of the shares.

If the recipient sells shares acquired upon exercise of an ISO at any time after the recipient has held the shares for at least one year after the date we issue such shares to the recipient pursuant to the recipient’s exercise of the ISO and at least two years after the date we grant the recipient the ISO, then the recipient will recognize long-term capital gain or loss equal to the difference between the sales price and the purchase price paid for the shares upon exercise of the ISO.

The amount by which the fair market value of shares the recipient acquires upon exercise of an ISO (determined as of the date of exercise) exceeds the purchase price paid for the shares upon exercise of the ISO will be included as a positive adjustment in the calculation of the recipient’s “alternative minimum taxable income” in the year of exercise. In computing the alternative minimum taxable income, the tax basis of a share acquired on exercise of the ISO is increased by the amount of the adjustment taken into account with respect for that share for alternative minimum tax purposes in the year the ISO is exercised.

In the case of a disqualifying disposition of shares by a recipient that results in the recognition of ordinary income, we will be entitled to an income tax deduction equal to the amount of such ordinary income includible in income by the option holder subject to Section 162(m) of the Code, provided that the amount constitutes an ordinary and necessary business expense, and either the employee includes that amount in income or we timely satisfy our reporting requirements with respect to that amount.

If the recipient holds the shares for the requisite period described above, and therefore solely recognizes capital gain upon the sale of such shares, we will not be entitled to any income tax deduction.

Nonqualified Stock Options. The grant of an NSO to a recipient is generally not a taxable event for the recipient if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. Upon the exercise of an NSO, the recipient will generally recognize ordinary income equal to the excess of the fair market value of the shares the recipient acquires upon exercise (determined as of the date of exercise) over the purchase price paid for the shares upon exercise of the NSO. Subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation, we generally will be entitled to an income tax deduction as a compensation expense equal to the amount of such ordinary income realized by the option holder. Provided the shares are held as a capital asset, the recipient’s subsequent sale of the shares generally will give rise to capital gain or loss equal to the difference between the sale price and the sum of the purchase price paid for the shares plus the ordinary income recognized with respect to the shares, and such capital gain or loss will be taxable as long term or short term capital gain or loss depending upon the recipient’s holding period after exercise.

Stock Appreciation Rights. Where the stock appreciation rights are granted with a strike price equal to the fair market value of the underlying stock on the grant date, the holder of a SAR will recognize ordinary income equal to the value we pay (whether in cash, stock or a combination thereof) pursuant to the SAR on the date the holder receives payment. We will generally be entitled to an income tax deduction in an amount equal to the ordinary income recognized by the holder.



Stock Purchase Rights - Restricted Stock. Under the 2013 Plan, we are authorized to grant rights to purchase shares of restricted Common Stock subject to a right to repurchase such stock at the price paid by the participant if the participant’s employment relationship with us terminates prior to the lapse of such repurchase right. In general, there will be no tax consequences to a participant upon the grant of a right to purchase such restricted stock or upon purchase of such restricted stock. Instead, the participant will be taxed at ordinary income rates at the time our repurchase rights expire or are removed on an amount equal to the excess of the fair market value of the stock at that time over the amount the participant paid to acquire such stock. A participant who acquires restricted stock, however, may make an election under Section 83(b) of the Internal Revenue Code with respect to such stock. If such an election is made within 30 calendar days after the participant’s acquisition of the stock, the participant is taxed at ordinary income rates in the year in which the participant acquires the restricted stock. The ordinary income the participant must recognize is equal to the excess of the fair market value of the stock at the time of the participant’s acquisition of the stock (determined without regard to the restrictions) over the amount that the participant paid to acquire such stock. If a participant makes a timely election under Section 83(b) of the Internal Revenue Code with respect to restricted stock, the participant generally will not be required to report any additional income with respect to such restricted stock until he or she disposes of such stock, at which time he or she will generally recognize capital gain or loss (provided the shares are held as a capital asset) equal to the difference between the sales price and the fair market value of the stock at the time of the participant’s acquisition of the stock (determined without regard to the restrictions). In the event that a participant forfeits (as a result of a repurchase) restricted stock with respect to which an election under Section 83(b) of the Internal Revenue Code has been made, the participant ordinarily will not be entitled to recognize any loss for federal income tax purposes (except to the extent the amount realized by the participant at the time of such forfeiture is less than the participant’s purchase price for such stock). We generally will be entitled to a deduction equal to the amount of ordinary income, if any, recognized by a participant.

Other Awards. In addition to the awards described above, the 2013 Plan authorizes certain other types of awards that may include payments in cash, our Common Stock or a combination of cash and our Common Stock. The tax consequences of such awards will depend upon the specific terms of such awards. Generally, however, a participant who receives an award payable in cash will recognize ordinary income, and we will be entitled to a deduction, with respect to such award at the earliest time at which the participant has an unrestricted right to receive the amount of the cash payment. In general, the sale or grant of stock to a participant under the 2013 Plan will be a taxable event at the time of the sale or grant if such stock at that time is not subject to a substantial risk of forfeiture or is transferable within the meaning of Section 83 of the Internal Revenue Code in the hands of the participant. For such purposes, stock is ordinarily considered to be transferable if it can be transferred to another person who takes the stock free of any substantial risk of forfeiture. In such case, the participant will recognize ordinary income, and we will be entitled to a deduction, equal to the excess of the fair market value of such stock on the date of the sale or grant over the amount, if any, that the participant paid for such stock. Stock that, at the time of receipt by a participant, is subject to restrictions that constitute a substantial risk of forfeiture and that is not transferable within the meaning of Section 83 of the Internal Revenue Code generally will be taxed under the rules applicable to restricted stock as described above.

Withholding. In the event that an optionee or other recipient of an award under the 2013 Plan is our employee, we generally will be required to withhold applicable federal income taxes with respect to any ordinary income recognized by such optionee or other award recipient in connection with stock options or other awards under the 2013 Plan.

Certain Additional Rules Applicable to Awards. The terms of awards granted under the 2013 Plan may provide for accelerated vesting in connection with a change in control. In that event, and depending upon the individual circumstances of the recipient, certain amounts with respect to such awards may constitute “excess parachute payments” under the “golden parachute” provisions of the Internal Revenue Code. Under these provisions, a participant will be subject to a 20% excise tax on any “excess parachute payments” and we will be denied any deduction with respect to such payment.

We generally are entitled to a deduction equal to the ordinary income recognized by a recipient in connection with an award. However, our deduction (including the deduction related to ordinary income recognized by a recipient) for compensation paid to our Chief Executive Officer and each of our other three most highly compensated officers (other than our Chief Financial Officer) may be limited to $1 million per person annually. Depending on the nature of the award, all or a portion of the ordinary income attributable to certain awards granted under the 2013 Plan may be included in the compensation subject to such deduction limitation.

Interest of Certain Persons in Matters to Be Acted Upon

Each of our current directors, executive officers and employees is eligible to receive awards under the 2013 Plan. The Administrator has the discretion to determine which eligible persons will receive awards under the 2013 Plan. As a result, future participation in the 2013 Plan by executive officers, directors and other employees is not determinable.



New Plan Benefits

The Compensation Committee will have full discretion to determine the number and amount of awards to be granted to employees under the 2013 Plan, subject to the terms of the plan. Therefore, the future benefits or amounts that would be received by the executive officers, directors, and employees, under the 2013 Plan are not determinable at this time. However, the following table sets forth the options issued under the 2013 Plan that have been granted related to the fiscal year ended December 31, 2016 to the following persons or groups: (i) each of our Named Executive Officers, (ii) our current executive officers as a group, (iii) all current directors who are not employees as a group, and (iv) all employees who are not executive officers.
NamePositionNumber of Securities Underlying Options Granted
George F. Tidmarsh, M.D., Ph.D.President, Chief Executive Officer and Secretary214,700
Lakhmir S. Chawla, M.D.Chief Medical Officer64,100
Dennis M. MulroyChief Financial Officer64,100
Jennifer A. CarverChief Operating Officer64,100
All current executive officers as a group471,100
All directors who are not employees as a group40,000
All employees, other than executive officers, as a group1,157,875

Vote Required

The approval of a majority of the votes cast affirmatively or negatively is required to approve this Proposal. Further, approval of this Proposal also requires the affirmative vote of a majority of the shares necessary to constitute a quorum for the Annual Meeting. As a result, broker non-votes and abstentions will be disregarded in determining whether the affirmative votes cast represent a majority of the total number of votes cast on this Proposal. However, a large number of abstentions or broker non-votes could prevent approval of this Proposal under the majority-of-the-quorum requirement.

Recommendation of the Board of Directors

The Board of Directors unanimously recommends a vote “FOR” approval of the foregoing resolution. Proxies will be so voted unless shareholders specify otherwise in their proxies.



CORPORATE GOVERNANCE

Board Leadership Structure; Risk Management

Our business affairs are managed under the direction of our Board, which currently consists of 5 members. Each of our current directors will continue to serve until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. The role of our Chairman of the Board is separate from our Principal Executive Officer. The Board has determined that this structure continues to be appropriate at this time.

Our Board is responsible for oversight of our risk management policies and procedures. We are exposed to a number of risks, including financial risks, strategic and operational risks and risks relating to regulatory and legal compliance. The Board will regularly discuss with management our major risk exposures highlighting any new risks that may have arisen since they last met and the steps management has taken to monitor and control such exposures, including the guidelines and policies to govern the process by which risk assessment and risk management are undertaken.

The Board oversees the management of risk exposure and risk mitigation in various areas including: (i) risks relating to our employment policies and executive compensation plans and arrangements; (ii) financial risks and taking appropriate actions to help ensure quality financial reporting and appropriately conservative investment practices; and (iii) risks associated with the independence of the Board and potential conflicts of interest. The Audit Committee reviews policies with respect to risk assessment and risk management and consults with outside resources as appropriate on other matters that could have a significant impact on the Company’s consolidated financial statements. The Audit Committee also reviews policies with respect to financial risk and makes recommendations to the Board. The Board’s administration of its risk oversight function has not affected the Board’s leadership structure, which separates the roles of our Chairman of the Board and our Principal Executive Officer.

Director Independence

Our business affairs are managed under the direction of our Board, which is currently composed of five5 directors. Consistent with NASDAQNasdaq listing requirements, our Board hasmakes an annual determination of the independence of our directors. This determination is made in conjunction with each annual meeting of shareholders. In connection with the 2020 Annual Meeting of Shareholders, the Board had determined that as of the Record Date,Mr. Johnson, Ms. Douglass,Johnson, Mr. JohnsonRamsay and Mr. Rosen are “independent” within the meaning of NASDAQNasdaq Marketplace Rules 5605(b) and 5605(a)(2). During the year ended December 31, 2016, the Board met or took action by unanimous written consent six times (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of: (i) the total number of meetings of the Board held during the period for which he or she has been a director; and (ii) the total number of meetings held by all committeesThere are no family relationships among any of our Board on which hedirectors or she served during the periods that he or she served.executive officers.

Committees of the Board of DirectorsCommittees

Our Board has three standing committees: an audit committee;committee (the “Audit Committee”); a compensation committee;committee (the “Compensation Committee”); and a corporate governance and nominating committee. All committee members have been determined to be independent.(the “Corporate Governance and Nominating Committee”). The committees operate under written charters that are available for viewing on our website at www.ljpc.com, under “Investor Relations.” Additionally, until a Chief Executive Officer is hired, a committee of the Board, comprised of Kevin Tang and Craig Johnson, will provide Board-level oversight of the Company’s management team.

Audit Committee.

It is the responsibility of the Audit Committee to oversee our accounting and financial reporting processes and the audits of our consolidated financial statements. In addition, the Audit Committee assists the Board in its oversight of our compliance with legal and regulatory requirements. The specific duties of the Audit Committee include: monitoring the integrity of our financial process and systems of internal controls regarding finance, accounting and legal compliance; selecting our independent auditor; monitoring the independence and performance of our independent auditor; and providing an avenue of communication among the independent auditor, our management and our Board. The Audit Committee has the authority to conduct any investigation it feels appropriate to fulfill its responsibilities, and it has direct access to all of our employees and to the independent auditor. The Audit Committee also has the ability to retain, at our expense and without further approval of the Board, special legal, accounting or other consultants or experts that it deems necessary in the performance of its duties. The Audit Committee met or took action by unanimous written consent four4 times in 2016. Theduring the year ended December 31, 2019. In 2019, the Audit Committee iswas comprised of three members: Craig Johnson, Laura Johnson and Robert Rosen and Laura Douglass.Rosen. Craig Johnson is the chairChairman of the Audit Committee and has been determined to qualify as an “audit committee


financial expert” as that term is deemed to bedefined under the audit committee's financial expert. As of the Record Date, eachSEC rules and regulations. Each member of the Audit Committee metmeets the requirements for independence under the listing standards of the NASDAQNasdaq Capital Market and the Securities and Exchange Commissions (the “SEC”) rules and regulations, as well as metand also meets the requirements for financial literacy and sophistication under the applicable listing standards.

Report of the Audit Committee

The Audit Committee oversees our financial reporting process. Management has the primary responsibility for the consolidated financial statements and the reporting process, including our system of internal control over financial reporting. In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 with management, including a discussion of the quality, not merely the acceptability, of the accounting and financial reporting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements.

The Audit Committee reviewed our audited consolidated financial statements with our independent auditor, which is responsible for expressing an opinion on the conformity of those audited consolidated financial statements with U.S. generally accepted accounting principles, including a discussion of such matters as are required to be discussed under U.S. generally accepted auditing standards. In addition, the Audit Committee has discussed with the independent auditor the matters required to be discussed, and received from them the written disclosures and letter required, by the applicable requirements of the Public Company Accounting Oversight Board and SEC, including with respect to its independence from us and our management. The Audit Committee has also considered the compatibility of the independent auditor’s provision of non-audit services to us with the auditor’s independence.

The Audit Committee discussed with our independent auditor the overall scope and plan for its audit. The Audit Committee met with the independent auditor, with and without management present, to discuss the results of its examinations, its evaluations of our internal controls and the overall quality of our financial reporting.

Based on the reviews and discussions referred to above, the Audit Committee recommended that our audited consolidated financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2019 for filing with the SEC. This report is provided by the following directors, who perform the functions of the Audit Committee:

Craig Johnson, Chairman of Audit Committee
Laura Johnson
Robert Rosen

Compensation Committee.

It is the responsibility of the Compensation Committee to assist the Board in discharging the Board’s responsibilities regarding the compensation of our employees, officers and directors. The specific duties of the Compensation Committee include: making recommendations to the Board regarding the corporate goals and objectives relevant to executive compensation; evaluating our executive officers’ performance in light of such goals and objectives; recommending compensation levels to the Board based uponon such evaluations; administering our incentive compensation plans, including our equity-based incentive plans; making recommendations to the Board regarding our overall compensation structure, policies and programs; and reviewing the Company’s compensation disclosures. Additional information regarding the processes and procedures of the Compensation Committee is provided below under the caption “Executive Compensation.” The Compensation Committee met or took action by unanimous written consent five times in 2016.once during the year ended December 31, 2019. The Compensation Committee is comprised of two members: Craig Johnson and Laura Douglass.Johnson. Craig Johnson is the chairChairman of the Compensation Committee. As of the Record Date, eachEach member of the Compensation Committee metmeets the requirements for independence under the listing standards of the NASDAQNasdaq Capital Market and the SEC rules and regulations.

Nominating and Corporate Governance andCommittee

The primary responsibilities of our Nominating Committee. It is the responsibility of theand Corporate Governance Committee are to develop and recommend to the Board criteria for identifying and evaluating qualified candidates for directorships and to make recommendations to the Board regarding candidates for election or reelection to the Board at each annual meeting of shareholders. In addition, the Nominating and Corporate Governance Committee is responsible for making


recommendations to assist the Board: to identify qualified individuals to become directors ofBoard concerning corporate governance matters; the Board; to determine thestructure, composition and function of the Board and its committees; and to monitor and assess the effectivenesscompensation of directors for service on the Board and its committees. The specific dutiesNominating and Corporate Governance Committee is comprised of two members: Laura Johnson and Robert Rosen. Each member of the Nominating and Corporate Governance andCommittee meets the requirements for independence under the listing standards of the Nasdaq Capital Market. The Nominating Committee include: identifying, screening and recommending to the Board candidates for election to the Board; reviewing director candidates recommended by our shareholders; assisting in recruiting qualified director candidates to serve on the Board; monitoring the independence of current directors and nominees; and monitoring and assessing the relationship between the Board and our management with respect to the Board’s ability to function independently of management. The Corporate Governance and Nominating Committee met or took action by unanimous written consent one time in 2016. The Corporate Governance and Nominating Committee is comprised of two members: Laura Douglass and Robert Rosen. As ofduring the Record Date, each member of the Corporate Governance and Nominating Committee met the requirements for independence under the listing standards of the NASDAQ Capital Market.year ended December 31, 2019.



Corporate Governance Guidelines

We have adopted a setMeetings of Corporate Governance Guidelines that describe a number of our corporate governance practices. The Corporate Governance Guidelines are available for viewing on our website at www.ljpc.com, under “Investor Relations.”

Code of Ethics; Corporate Website

We have adopted a Code of Business Conduct and Ethics (the “Code of Ethics”) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial and accounting officer, or persons performing similar functions. Our Code of Ethics is posted on our corporate governance website located at www.ljpc.com, under “Investor Relations”. We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver. The corporate website may also be used to communicate other material developments to our shareholders from time to time, such as press releases, corporate presentations and presentations delivered at investor conferences. Shareholders are encouraged to regularly review the corporate website for any such updates.

Communications with the Board of Directors

Our shareholders may communicate with our Board or a particular director by sending a letter addressed toDuring the year ended December 31, 2019, the Board met or a particulartook action by unanimous written consent 10 times (including regularly scheduled and special meetings), and each director to: c/o Corporate Secretary, La Jolla Pharmaceutical Company, 10182 Telesis Court, 6th Floor, San Diego, California, 92121. All communications will be compiled by our Corporate Secretary and forwarded to the Board or the director accordingly.

Compensation Committee Interlocks and Insider Participation

During 2016, Dr. Tidmarsh was an employeeattended at least 90% of the Company. Noneaggregate of: (i) the total number of our executive officers served as a member of the Compensation Committee or as a director of another entity where such entity’s executive officers served on our Compensation Committee or Board.

Board Leadership Structure; Risk Management

The role of our Chairmanmeetings of the Board is separate fromheld during the Chief Executive Officer. Theperiod for which he or she has been a director; and (ii) the total number of meetings held by all committees of our Board has determinedon which he or she served during the periods that its structure is appropriate at this time givenhe or she served. We encourage all of our directors to attend our annual meeting of shareholders. We held our 2019 Annual Meeting of Shareholders on October 8, 2019, and one of the Company’s specific characteristics and circumstances, includingdirectors attended the Board’s commitment to independent Board and Committee leadership, and to fulfill the Board’s duties effectively and efficiently so that our business receives the undivided attention of the Chief Executive Officer.

Our Board is responsible for oversight of our risk management policies and procedures. We are exposed to a number of risks, including financial risks, strategic and operational risks and risks relating to regulatory and legal compliance. The Board will regularly discuss with management our major risk exposures and the steps management has taken to monitor and control such exposures, including the guidelines and policies to govern the process by which risk assessment and risk management are undertaken, and highlighting any new risks that may have arisen since they last met.

The Board oversees the management of risk exposure and risk mitigation in various areas including: (i) risks relating to our employment policies and executive compensation plans and arrangements; (ii) financial risks and taking appropriate actions to help ensure quality financial reporting and appropriately conservative investment practices; and (iii) risks associated with the independence of the Board and potential conflicts of interest. The Audit Committee reviews policies with respect to risk assessment and risk management and consults with outside resources as appropriate on other matters that could have a significant impact on the Company’s financial statements. The Audit Committee also reviews policies with respect to financial risk and makes recommendations to the Board. The Board’s administration of its risk oversight function has not affected the Board’s leadership structure, which separates the roles of our Chairman of the Board and our Chief Executive Officer.meeting.

Director Nominations

Our Corporate Governance and Nominating Committee regularly assesses the appropriate size of the Board and whether any vacancies on the Board are expected due to retirement or otherwise. In the event that vacancies are anticipated or otherwise arise, the Corporate Governance and Nominating Committee may utilize a variety of methods for identifying and evaluating director candidates. Candidates may come to the attention of the Corporate Governance and Nominating Committee through current directors, professional search firms, shareholders or other persons. Once the Corporate Governance and


Nominating Committee has identified a prospective nominee, it will evaluate the prospective nominee in the context of the then-current constitution of the Board and will consider a variety of other factors, including the prospective nominee’s business, biotechnology,industry, finance and financial reporting experience, andas well as attributes that would be expected to contribute to an effective Board. The Corporate Governance and Nominating Committee seeks to identify nominees who possess a wide range of experience, skills and areas of expertise, knowledge and business judgment. Our Corporate Governance and Nominating Committee thus considers a broad range of factors relating to the qualifications and background of nominees, which may include diversity, which is not only limited to race, gender or national origin, but also includes diversity of experience and skills. We have no formal policy regarding Board diversity. Our Corporate Governance and Nominating Committee’s priority in selecting directors is the identification of persons who will further the interests of our shareholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among directors, and professional and personal experiences and expertise relevant to our growth strategy. Successful nominees must have a history of superior performance or accomplishments in their professional undertakings and should have the highest personal and professional ethics and values. The Corporate Governance and Nominating Committee assesses its effectiveness in balancing these considerations when assessing the composition of the Board. The Corporate Governance and Nominating Committee does not evaluate shareholder nominees differently than any other nominee.

Pursuant to procedures set forth in the Company’s Bylaws, as amended and restated (the “Bylaws”“Bylaws”), our Corporate Governance and Nominating Committee will consider shareholder nominations for directors if we receive timely written notice, in proper form, of the intent to make a nomination at a meeting of shareholders. To be timely, the notice must be received within the time frame discussed in our Bylaws. To be in proper form, the notice must, among other matters, include each director nominee’s written consent to serve as a director if elected, a description of all arrangements or understandings between the nominating shareholder and each director nominee and information about the nominating shareholder and each director nominee. A copy of our Bylaws will be provided uponon written request to our Corporate Secretary.

Director Attendance at Annual MeetingsShareholder Communications

Our Board has adopted a policy that encourages our directors to attend our annual shareholder meeting. We held our 2016 annual shareholder meeting on August 23, 2016, and three of the Company’s directors were present in person for such meeting.

Report of the Audit Committee

The Audit Committee oversees our financial reporting process. Management has the primary responsibility for the financial statements and the reporting process, including our system of internal control over financial reporting. In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed the audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2016 with management, including a discussion of the quality, not merely the acceptability, of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements.

The Audit Committee reviewed our audited financial statementsshareholders may communicate with our independent auditor, which is responsible for expressing an opinion onBoard or a particular director by sending a letter addressed to the conformity of those audited financial statements with accounting principles generally accepted inBoard or a particular director to our Secretary at La Jolla Pharmaceutical Company, 4550 Towne Centre Court, San Diego, California, 92121. All communications will be compiled by our Secretary and forwarded to the United States, including a discussion ofBoard, or the director, accordingly. The Secretary opens, logs and forwards all such matters as are required to be discussed under auditing standards generally accepted in the United States. In addition, the Audit Committee has discussed with the independent auditor its independence from us and our management, including as set forth in Auditing Standard 1301: Communications with Audit Committees (formerly Auditing Standard No. 16). The Audit Committee has also considered the compatibility of the independent auditor’s provision of non-audit services to us with the auditor’s independence.

The Audit Committee discussed with our independent auditor the overall scope and plan for its audit. The Audit Committee met with the independent auditor, with and without management present, to discuss the results of its examinations, its evaluations of our internal controls and the overall quality of our financial reporting.

Based upon the reviews and discussions referred to above, the Audit Committee recommended that our audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2016 for filing with the SEC. This report is provided by the following directors, who perform the functions of the Audit Committee:

Craig A. Johnson, Chair of Audit Committee
Robert H. Rosen
Laura L. Douglasscorrespondence (other than



advertisements or other solicitations) to the Board, or the director, accordingly, unless a director has requested that the Secretary forward correspondence unopened.

Section 16(a) Beneficial Ownership Reporting ComplianceCorporate Governance Guidelines

UnderWe have adopted a set of Corporate Governance Guidelines that describe a number of our corporate governance practices. The Corporate Governance Guidelines are available for viewing on our website at www.ljpc.com, under “Investor Relations.”

Code of Business Conduct and Ethics; Corporate Website

We have adopted a Code of Business Conduct and Ethics (the “Code of Ethics”) that applies to all of our directors, executive officers and employees, including our principal executive officer, principal financial and accounting officer and persons performing similar functions. Our Code of Ethics is available for viewing on our website at www.ljpc.com, under “Investor Relations.” We intend to disclose future amendments to, or waivers of provisions with respect to our officers and directors in, the securities lawsCode of Ethics on our website within 4 business days following the date of the United States,amendment or waiver. Our website may also be used to communicate other material developments to our directorsshareholders from time to time, such as press releases, corporate presentations and officers and persons who own more than 10% ofpresentations delivered at investor conferences. Shareholders are encouraged to regularly review our equity securities are required to report their initial beneficial ownership of our equity securities andwebsite for any subsequent changes in that beneficial ownership to the SEC. Specific due dates for these reports have been established, and we are required to disclose any known late filings during the year ended December 31, 2016. To our knowledge, based solely upon our review of the copies of such reports required to be furnished to us during the year ended December 31, 2016, all of these reports were timely filed.updates.



EXECUTIVE OFFICERS

Our executive officers, and their respective ages as of July 1, 2017and respective biographies are set forth below, as well as biographies for officers other than Dr. Tidmarsh, whose biography is set forth under Proposal 1.below.
Name Age Position
George F. Tidmarsh, M.D., Ph.D.57
President, Chief Executive Officer, Secretary and Director
Lakhmir S. Chawla, M.D. 4649
 Chief Medical Officer
Dennis M. Mulroy 6265
 Chief Financial Officer,
Jennifer A. Carver63
Chief Operating Principal Executive Officer and Secretary
James M. Rolke 4851
 Chief Scientific Officer
Darryl Wellinghoff51
Chief Commercial Officer

Dr. Lakhmir “Mink” S. Chawla, M.D.has been theserved as our Chief Medical Officer of the Company since July 2015. Dr. Chawla has more than 20 years of medical experience with particular expertise in critical care and nephrology. Dr. Chawla has been an active investigator in the field of critical care nephrology since 2002. Previously, Dr. Chawla was an Associate Professor of Medicine at the George Washington University from 2008From 2014 to 2015, where he had dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla was also theserved as Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center fromCenter. From 2002 to 2014, to 2015. During his tenure at George Washington, Dr. Chawla was on faculty at the designerGeorge Washington University and lead investigatorachieved the rank of a pilot study called the ATHOS (Angiotensin II for the TreatmentProfessor of High Output Shock) trial, which served as the basis for the Company’s ongoing ATHOS 3 clinical study.Medicine. Dr. Chawla received a B.A. degree in medical science from Boston University and an M.D. degree from theRutgers New Jersey Medical School.

Dennis M. Mulroy has been theserved as our Chief Financial Officer of the Company since April 2015. Mr. Mulroy has more than 25 years of financial management experience, including leadership positions in publicly traded biotechnology, life sciences,medical service and medical device companies. PriorFrom 2005 to joining La Jolla, Mr. Mulroy2015, he served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group, Inc. since 2005. PriorFrom 2004 to joining Taxus Cardium,2005, Mr. Mulroy served as Chief Financial Officer of Molecular Imaging, Inc. andFrom 2001 to 2003, he served as Chief Financial Officer of SeraCare Life Sciences, Inc., and held financial management positions of increasing responsibility at several other companies. Mr. Mulroy began his career as a Certified Public Accountant withat Ernst & Young LLP in San Diego.LLP. Mr. Mulroy received a B.S. degree in business administration, with an emphasis in accounting, from the University of San Diego.

Jennifer A. Carver has beenDiego and is a Certified Public Accountant (inactive) in the Chief Operating Officer since January 2017. Prior to her appointment as Chief Operating Officer, Ms. Carver held a numberstate of operational roles of increasing responsibility since joining the Company in February 2014, most recently as Senior Vice President, Operations of the Company. Ms. Carver has more than 20 years of cross-functional leadership experience in pharmaceutical drug development and the healthcare industry. Prior to joining La Jolla, Ms. Carver was Senior Director of Project Management at Spectrum Pharmaceuticals, Inc., leading the NDA and launch activities for Beleodaq®, an FDA-approved, anti-cancer agent, from 2012 to 2014. Previously, she held various roles at Allos Therapeutics, Inc. from 2001 to 2012, including Project Manager for Folotyn®, an FDA-approved, anti-cancer agent, and led integration activities following the acquisition of Allos by Spectrum Pharmaceuticals in 2012. Ms. Carver received a B.S.N. and M.B.A. from the University of Colorado.California.

James M. Rolke has been theserved as our Chief Scientific Officer of the Company since January 2017. Prior to his appointment as Chief Scientific Officer, Mr. Rolke2017 and previously held various positions, of increasing responsibility since joining the Company in January 2012, most recently serving as Vice President of Research & Development. Mr. Rolke has over 25 years of research and development experience in the biotechnology industry. PriorDevelopment, from 2012 to joining La Jolla, Mr. Rolke was2017. From 2009 to 2012, he served as Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi) from. From 2007 to 2009, to 2012. Previously, Mr. Rolke served as Director of Operations at Prospect Therapeutics, Inc. fromFrom 2006 to 2007, he served as Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc. From 2003 to 2009, and held research and development positions2006, Mr. Rolke served as Manager of increasing responsibilityProcess Development at several other companies.GlycoGenesys, Inc. Mr. Rolke received a B.S. degree in chemistry from Keene State College.


Darryl Wellinghoff has served as our Chief Commercial Officer since March 2019. From 2016 to 2018, he served as the Executive Vice President at Mainstreet Health. From 2001 to 2016, Mr. Wellinghoff held various positions at The Medicines Company, most recently serving as Senior Vice President, Americas. From 1997 to 2001, he held various commercial positions at Bristol-Myers Squibb. Mr. Wellinghoff received a B.A. degree in English from Florida State University.




EXECUTIVE COMPENSATION

Summary Compensation Discussion and Analysis

OverviewTable

The following Compensation Discussion and Analysis describes the material elements of compensation earned by our four executive officers serving during 2016, which included the Chief Executive Officer, Chief Medical Officer, Chief Financial Officer and Chief Operating Officer (who held the title of Senior Vice President, Operations during 2016) who are collectively referred to herein as the Company’s Named Executive Officers. In January 2017, James Rolke was promoted to the position of Chief Scientific Officer. In that capacity, Mr. Rolke is deemed an executive officer. However, because Mr. Rolke was not serving as an executive officer at any time during 2016, Mr. Rolke is not included as a Named Executive Officertable provides information for the yearyears ended December 31, 2016.

Compensation Philosophy2019 and Objectives

Our goal is2018 concerning the compensation paid or awarded to provide a competitive total compensation package with significant emphasis on pay for performance. Accordingly, we favor equityour principal executive officer and discretionary awards over guaranteed cash compensation in order to drive accomplishments that enhance shareholder value and align the interests of ourtwo other most highly compensated executive officers and our shareholders. This means that our executive officers will not realize the total potential value of their compensation package unless performance goals, which are directly tied to our corporate performance, are achieved. The Compensation Committee believes that our executive compensation program is appropriately designed and reasonable in light of the executive compensation programs of our peer group companies and responsible in that it is designed to incentivize our management team to achieve our short-term and long-term corporate objectives, while effectively managing business risks and challenges.(the “Named Executive Officers” or “NEOs”):

Based on the foregoing objectives, executive compensation is based on three primary components: base salary, annual incentive bonuses and equity awards. The Compensation Committee believes that cash compensation in the form of base salary and an annual incentive target bonus provides our executive officers with short-term rewards for success in operations, and that long-term compensation through equity awards (which consists mainly of stock options) aligns the objectives of management with those of our shareholders with respect to long-term performance and success. In addition, our executive officers receive benefits that are generally available to all of our employees. Our compensation-setting process includes reviewing the targeted overall compensation for each executive, and then allocating that compensation between base salary and incentive compensation (annual performance-based cash bonuses and equity incentive awards), based appropriately on industry and salary survey data for public companies of a similar market capitalization, size and stage of clinical development.
Name and Principal Position Year Salary 
Option
Awards(1)
 
Non-Equity
Incentive Plan
Compensation(2)
 
All Other
Compensation(3)
 Total
Current Named Executive Officers

        
Dennis Mulroy 2019 $382,000
 $143,948
 $76,400
 $10,739
 $613,087
     Chief Financial Officer,
Principal Executive Officer and Secretary
 2018 $370,000
 $253,398
 $75,000
 $13,188
 $711,586
             
Lakhmir Chawla, M.D. 2019 $458,000
 $130,333
 $91,600
 $10,611
 $690,544
     Chief Medical Officer 2018 $444,000
 $252,778
 $75,000
 $10,435
 $782,213
             
Darryl Wellinghoff (4)
 2019 $315,439
 $578,343
 $63,213
 $9,719
 $966,714
     Chief Commercial Officer 2018 $—
 $—
 $—
 $—
 $—
Former Named Executive Officers        
George Tidmarsh, M.D., Ph.D. (5)
 2019 $546,300
 $9,819
 $—
 $11,929
 $568,048
     Former President, Principal/Chief Executive Officer and Secretary 2018 $589,000
 $833,107
 $75,000
 $11,974
 $1,509,081
             
Jennifer Carver (6)
 2019 $376,200
 $9,290
 $—
 $388,420
 $773,910
     Former Chief Operating Officer 2018 $405,000
 $258,270
 $75,000
 $49,122
 $787,392

With respect to equity awards, these awards typically vest and become exercisable over a period of four years, consisting of an initial one-year cliff-vest, followed by monthly or quarterly vesting. However, we have also used performance-based vesting conditions and the combination of performance and time-based vesting conditions for certain awards. We believe that long-term value creation, contrasted with short-term gain, presents the best opportunity for employees to profit from these awards. In circumstances where performance-based equity awards have been granted, the events that trigger vesting are generally estimated to be achieved at least one year from the grant date, although shorter performance goals may be used in some cases. The Company has not historically used claw-back provisions or imposed holding periods for vested awards, although the Compensation Committee may consider whether such mechanisms might be appropriate in the future to mitigate risk.

Risk Management and Mitigation

In reviewing the compensation structure in fiscal 2016, we also considered how the Company’s compensation policies may affect the Company’s risk profile and whether compensation policies and practices may encourage risk-taking by employees. More specifically, we considered the general design philosophy of the Company’s policies for employees whose conduct would be most affected by incentives established by compensation policies. In considering these issues, we concluded that the use of performance-based bonuses and long-term equity awards did not appear to create undue risks for the Company or encourage excessive risk-taking behavior on the part of our executive officers.
(1)The amounts reported in this column represent the grant-date fair values of stock options granted to each NEO, calculated in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation-Stock Compensation. For a discussion of the assumptions used to calculate the value of our stock options, see Note 6 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. The grant-date fair values of stock options awarded in 2019 include stock options granted in January 2020 for services rendered in 2019. The grant-date fair values of stock options awarded in 2018 include stock options granted in January 2019 for services rendered in 2018.
(2)The amounts reported in this column represent each NEO’s performance-based cash bonus paid.
(3)Unless otherwise indicated, the amounts reported in this column represent the Company’s matching contribution to each NEO’s 401(k) plan account and life insurance premiums paid by the Company.
(4)The grant-date fair values of stock options granted to Mr. Wellinghoff in 2019 include stock options granted on becoming Chief Commercial Officer of the Company.
(5)On November 23, 2019, Dr. Tidmarsh resigned as the President and Chief Executive Officer of the Company and as a member of the Company’s Board of Directors.
(6)On November 23, 2019, Ms. Carver resigned as the Company’s Chief Operating Officer. For the year ended December 31, 2019, all other compensation includes $372,333 for: (a) severance payments that Ms. Carver will receive over the 10-month period following her resignation; and (b) continued medical coverage over the 12-month period following her resignation.



Outstanding Equity Awards as of December 31, 2019

The following table presents information regarding the outstanding option awards held by each of the NEOs as of December 31, 2019:
  Option Awards
Name Vesting Commencement Date 
Number of Securities
Underlying Unexercised
Options (#) Exercisable
 
Number of Securities
Underlying Unexercised
Options (#) Unexercisable
 
Option
Exercise
Price ($)
 
Option
Expiration
Date(1)
Current Named Executive Officers        
Dennis Mulroy 4/6/2015 60,000
 —
 $18.23
 4/6/2025
  12/21/2015 41,500
 —
 $28.24
 12/21/2025
  1/4/2017 46,740
 17,360
(2) 
$19.19
 1/4/2027
  12/11/2017 24,500
 24,500
(2) 
$28.10
 12/11/2027
  12/27/2017 3,350
 3,350
(2) 
$32.47
 12/27/2027
  10/15/2018 6
 16
(2) 
$16.25
 10/15/2028
  10/31/2018 6
 16
(2) 
$16.30
 10/31/2028
  11/15/2018 7
 17
(2) 
$14.90
 11/15/2028
  11/30/2018 7
 19
(2) 
$14.47
 11/30/2028
  12/14/2018 7
 21
(2) 
$12.80
 12/14/2028
  12/31/2018 10
 29
(2) 
$9.43
 12/31/2028
  1/15/2019 —
 316
(2) 
$6.75
 1/15/2029
  1/23/2019 —
 53,000
(2) 
$5.99
 1/23/2029
  1/31/2019 —
 63
(2) 
$6.04
 1/31/2029
  2/15/2019 —
 60
(2) 
$6.23
 2/15/2029
  2/28/2019 —
 65
(2) 
$5.70
 2/28/2029
  3/15/2019 —
 49
(2) 
$7.64
 3/15/2029
  3/29/2019 —
 59
(2) 
$6.43
 3/29/2029
  4/15/2019 —
 261
(2) 
$7.16
 4/15/2029
  4/30/2019 —
 233
(2) 
$8.05
 4/30/2029
  5/15/2019 —
 285
(2) 
$6.57
 5/15/2029
  5/31/2019 —
 347
(2) 
$5.39
 5/31/2029
  6/14/2019 —
 193
(2) 
$9.71
 6/14/2029
  6/28/2019 —
 202
(2) 
$9.25
 6/28/2029
  7/15/2019 —
 203
(2) 
$9.24
 7/15/2029
  7/31/2019 —
 224
(2) 
$8.36
 7/31/2029
  8/15/2019 —
 198
(2) 
$9.43
 8/15/2029
  8/30/2019 —
 196
(2) 
$9.57
 8/30/2029
  9/13/2019 —
 171
(2) 
$10.92
 9/13/2029
  9/30/2019 —
 213
(2) 
$8.80
 9/30/2029
  10/15/2019 —
 224
(2) 
$8.38
 10/15/2029
  10/31/2019 —
 267
(2) 
$7.02
 10/31/2029
  11/15/2019 —
 62
(2) 
$6.02
 11/15/2029
  11/29/2019 —
 138
(2) 
$2.74
 11/29/2029
  12/13/2019 —
 112
(2) 
$3.35
 12/13/2029
  12/31/2019 —
 16
(2) 
$3.93
 12/31/2029
Lakhmir Chawla, M.D. 2/6/2015 60,000
 —
 $17.34
 2/6/2025
  8/31/2015 60,000
 —
 $35.58
 8/31/2025
  8/31/2015 30,000
 —
 $35.58
 8/31/2025
  12/21/2015 58,700
 —
 $28.24
 12/21/2025


  1/4/2017 46,740
 17,360
(2) 
$19.19
 1/4/2027
  12/11/2017 24,500
 24,500
(2) 
$28.10
 12/11/2027
  12/27/2017 3,350
 3,350
(2) 
$32.47
 12/27/2027
  10/15/2018 4
 11
(2) 
$16.25
 10/15/2028
  10/31/2018 4
 11
(2) 
$16.30
 10/31/2028
  11/15/2018 4
 12
(2) 
$14.90
 11/15/2028
  11/30/2018 4
 12
(2) 
$14.47
 11/30/2028
  12/14/2018 4
 13
(2) 
$12.80
 12/14/2028
  12/31/2018 6
 17
(2) 
$9.43
 12/31/2028
  1/23/2019 —
 53,000
(2) 
$5.99
 1/23/2029
  1/15/2019 —
 72
(2) 
$6.75
 1/15/2029
  1/31/2019 —
 37
(2) 
$6.04
 1/31/2029
  2/15/2019 —
 36
(2) 
$6.23
 2/15/2029
  2/28/2019 —
 40
(2) 
$5.70
 2/28/2029
  3/15/2019 —
 29
(2) 
$7.64
 3/15/2029
  3/29/2019 —
 35
(2) 
$6.43
 3/29/2029
  4/15/2019 —
 94
(2) 
$7.16
 4/15/2029
  4/30/2019 —
 84
(2) 
$8.05
 4/30/2029
  5/15/2019 —
 102
(2) 
$6.57
 5/15/2029
  5/31/2019 —
 126
(2) 
$5.39
 5/31/2029
  6/14/2019 —
 69
(2) 
$9.71
 6/14/2029
  6/28/2019 —
 73
(2) 
$9.25
 6/28/2029
  7/15/2019 —
 73
(2) 
$9.24
 7/15/2029
  7/31/2019 —
 80
(2) 
$8.36
 7/31/2029
  8/15/2019 —
 72
(2) 
$9.43
 8/15/2029
  8/30/2019 —
 70
(2) 
$9.57
 8/30/2029
  9/13/2019 —
 62
(2) 
$10.92
 9/13/2029
  9/30/2019 —
 76
(2) 
$8.80
 9/30/2029
  10/15/2019 —
 81
(2) 
$8.38
 10/15/2029
  10/31/2019 —
 96
(2) 
$7.02
 10/31/2029
  11/15/2019 —
 111
(2) 
$6.02
 11/15/2029
  11/29/2019 —
 247
(2) 
$2.74
 11/29/2029
  12/13/2019 —
 201
(2) 
$3.35
 12/13/2029
  12/31/2019 —
 172
(2) 
$3.93
 12/31/2029
Darryl Wellinghoff 3/5/2019 —
 80,000
(2) 
$7.00
 3/5/2019
  4/15/2019 —
 261
(2) 
$7.16
 4/15/2029
  4/30/2019 —
 233
(2) 
$8.05
 4/30/2029
  5/15/2019 —
 285
(2) 
$6.57
 5/15/2029
  5/31/2019 —
 347
(2) 
$5.39
 5/31/2029
  6/14/2019 —
 193
(2) 
$9.71
 6/14/2029
  6/28/2019 —
 202
(2) 
$9.25
 6/28/2029
  7/15/2019 —
 203
(2) 
$9.24
 7/15/2029
  7/31/2019 —
 224
(2) 
$8.36
 7/31/2029
  8/15/2019 —
 198
(2) 
$9.43
 8/15/2029
  8/30/2019 —
 196
(2) 
$9.57
 8/30/2029
  9/13/2019 —
 171
(2) 
$10.92
 9/13/2029
  9/30/2019 —
 213
(2) 
$8.80
 9/30/2029
  10/15/2019 —
 224
(2) 
$8.38
 10/15/2029
  10/31/2019 —
 267
(2) 
$7.02
 10/31/2029
  11/15/2019 —
 311
(2) 
$6.02
 11/15/2029


  11/29/2019 —
 17
(2) 
$2.74
 11/29/2029
Former Named Executive Officers        
George Tidmarsh, M.D., Ph.D. (3)
 4/3/2014 181,000
 —
 $10.84
 4/3/2024
  2/23/2015 300,000
 —
 $19.69
 2/23/2025
  8/31/2015 30,000
 —
 $35.58
 8/31/2025
  12/21/2015 282,979
 —
 $28.24
 12/21/2025
  1/4/2017 152,079
 —
 $19.19
 1/4/2027
  12/11/2017 87,688
 —
 $28.10
 12/11/2027
  12/27/2017 11,458
 —
 $32.47
 12/27/2027
  10/15/2018 24
 —
 $16.25
 10/15/2028
  10/31/2018 22
 —
 $16.30
 10/31/2028
  11/15/2018 24
 —
 $14.90
 11/15/2028
Jennifer Carver (4)
 2/17/2014 18,000
 —
 $7.26
 2/17/2024
  5/22/2014 10,000
 —
 $7.69
 5/22/2024
  11/20/2014 12,000
 —
 $19.80
 1/9/2025
  2/23/2015 23,500
 —
 $19.69
 2/23/2025
  8/31/2015 15,000
 —
 $35.58
 8/31/2025
  12/21/2015 49,938
 —
 $28.24
 12/21/2025
  1/4/2017 45,404
 —
 $19.19
 1/4/2027
  12/11/2017 23,479
 —
 $28.10
 12/11/2027
  12/27/2017 3,701
 —
 $32.47
 12/27/2027
  10/15/2018 23
 —
 $16.25
 10/15/2028
  10/31/2018 21
 —
 $16.30
 10/31/2028
  11/15/2018 24
 —
 $14.90
 11/15/2028
(1)All stock options expire 10 years from the grant date.
(2)The stock option vests and becomes exercisable with respect to 25% of the underlying shares of common stock on the one-year anniversary of the vesting commencement date and then vests ratably on a monthly basis over the next three years.
(3)On November 23, 2019, Dr. Tidmarsh resigned as the President and Chief Executive Officer of the Company and as a member of the Company’s Board of Directors. All outstanding unvested equity awards were cancelled on such date.
(4)On November 23, 2019, Ms. Carver resigned as the Company’s Chief Operating Officer. All outstanding unvested equity awards were cancelled on such date.

Compensation Arrangements with Named Executive Officers

All compensation arrangements with NEOs constitute “at-will” employment, meaning an NEO can terminate employment at any time, for any reason or for no reason. Similarly, the Company is free to terminate an NEO at any time, for any reason or for no reason. NEOs receive an annual base salary and are eligible to earn an annual performance-based cash bonus. In determining the annual performance-based cash bonus for each NEO, the NEO’s annual base salary is multiplied by his or her target bonus percentage, and the resulting amount is then multiplied by the corporate performance percentage approved by the Board, which is dependent on the achievement of corporate performance goals. NEOs are also eligible to receive an equity interest in the Company in the form of option awards. Option awards generally vest over a 4-year period from either the date of grant or the commencement of service and are subject to continued service requirements. Option awards may be subject to accelerated vesting by the Company in the event of an NEO’s termination of employment by reason of death or disability or in conjunction with a change in control. Compensation arrangements with NEOs do not otherwise provide for severance benefits.

Roles in Determining Compensation

Compensation Committee



The Compensation Committee has the responsibility of reviewing the appropriateness of the total compensation paid to our executive officers.employees. The Compensation Committee oversawreviewed and approvedpresented for Board approval all compensation arrangements and actions for our key employees in 2016,2019, including the Named Executive Officers. The Compensation Committee has delegated to the Chief Executive Officer certain administrative responsibilities under the Company’s equity compensation plan, allowing the Chief Executive Officer to make equity award grants, and set base salary and annual incentive targets, in each case within predetermined guidelines established by the Compensation Committee and limited to non-officer employees of the Company.NEOs.

Compensation Consultant

In 2016,2019, the Compensation Committee engaged the services of Barney & Barney,Anderson Pay Advisors LLC (“B&B”Anderson”), an independent insuranceexecutive compensation firm that provides compensation consulting services. The directive for B&BAnderson was to assist the Compensation Committee in its review of executive and director compensation practices, including the competitiveness of pay levels, executive compensation design and review and analysis of competitive data with respect to the Company’s peers in the industry. The Compensation Committee has the final authority to engage and terminate the services for consultants it may engage.of compensation consultants. The decision to engage B&BAnderson was not made, or recommended, by the Company’s management. B&B also provides insurance brokerage services to the Company outside of its services to the Compensation Committee. The Compensation Committee, after a review of the factors set forth in Section 10C-1 of the Securities and Exchange Act of 1934 (the “Exchange Act”), has determined that B&BAnderson is independent, and neither the insurance brokerage work andservices nor the compensation consulting workservices performed by B&B did notAnderson present any conflicts of interest.

Say-on-Pay

On June 5, 2013 and August 23, 2016, the Company provided shareholders a “say-on-pay” advisory vote on its executive compensation under Section 14A of the Securities Exchange Act of 1934, as amended. At the Company’s 2013 and 2016 annual meeting of shareholders, shareholders expressed support for the compensation of our Named Executive Officers, with a majority of the votes cast for approval of the “say-on-pay” advisory vote. The Compensation Committee carefully evaluated the results of these advisory votes. The Compensation Committee also considers many other factors in evaluating the Company’s executive compensation programs as discussed in this Compensation Discussion and Analysis, including the Compensation Committee’s assessment of the interaction of our compensation programs with our corporate business objectives, evaluations of our programs by external consultants, and review of peer group and survey data, each of which is evaluated in the context of the Compensation Committee’s fiduciary duty to act as the directors determine to be in shareholders’ best interests. While each of these factors bore on the Compensation Committee’s decisions regarding our Named Executive Officers’ compensation, the Compensation Committee did not make any changes to our executive compensation program and policies as a result of the “say-on-pay” advisory votes. The Company also provided shareholders a “say-on-frequency” advisory vote on June 5, 2013. As previously disclosed, in light of the results of such shareholder vote, the Board adopted a resolution to hold a “say-on-pay” vote once every three years. The next “say-on-pay” vote will be held at the Company’s 2019 annual meeting of shareholders, at which time the Company will also submit a new say-on-frequency vote for consideration.

Base Salary

Executive base salaries are based on job responsibilities, accountability and the experience of the individual. For 2016, the Compensation Committee sought to implement a policy of targeting base salaries for executives, including the Chief Executive Officer, at or near the 50th percentile of salaries of executives with similar roles at similar organizations, based on broad comparative data. In its assessment of executive compensation levels, B&B provided information that indicated that, using the Company’s identified peer group, executive cash compensation was slightly below the 50th percentile.

During its review of base salaries for executives and other key employees, the Compensation Committee primarily considered:
market data provided by publicly available industry surveys and B&B to ensure competitive compensation;
compensation data for public companies of a similar market capitalization, size and stage of clinical development;
individual performance of the executive for the prior year, including achievements and overall contribution to the Company’s growth and business success; and
internal review of the executive’s overall compensation relative to other executives at a similar level.


Defined Contribution Plan

The Compensation Committee considers these factors in the aggregate, without assigning weight to any specific factor, and not every factor was considered for each executive officer.

Salary levels are typically considered annually as part of our performance review process as well as upon promotion or other changes in job responsibilities. Merit increases are awarded based on the Compensation Committee’s subjective overall review of an executive’s performance of his or her job responsibilities. In addition, base salaries are reviewed annually to assure comparability with market practices. Market adjustments generally are reserved for those whose base salaries are substantially below market. In June 2016, the compensation committee reassessed the base salaries paid to the Executive Officers and based on a review of peer data, approved increases of 4.2% for Dr. Chawla, 6.1% for Mr. Mulroy, and 13.3% for Ms. Carver. Dr. Tidmarsh’s base salary remained unchanged. In the evaluation of performance for 2016, the Compensation Committee approved an increase of 2.5% in the base salaries for Dr. Tidmarsh, Dr. Chawla, Mr. Mulroy and Ms. Carver. Ms. Carver was promoted to Chief Operating Officer and received an additional promotion increase of 6%. These increases were effective commencing with the first pay period in 2017.

Annual Incentive Bonus

The annual performance-based cash bonus for the Named Executive Officers is determined based upon corporate performance and also individual achievements and performance, as warranted. The Compensation Committee, consistent with the overall corporate philosophy of keeping cash compensation for executives at or near the 50th percentile when compared to executives with similar roles at similar organizations, reviewed the target bonus potential payout for the Named Executive Officers together with other generally available market comparative data. The target bonus is set at an incentive level based on the executive’s accountability and potential impact on the Company’s performance. Accordingly, the more control and accountability that an executive has over the Company’s performance, the greater the percentage of that executive’s total compensation is dependent on annual performance-based cash bonus awards. The targeted bonus payout for 2016 set at the beginning of the year was 50% of base salary for Dr. Tidmarsh and 35% of base salary for each of Dr. Chawla, Mr. Mulroy and Ms. Carver. In determining the annual performance-based cash bonus opportunity for executives, the executive’s annual base salary is multiplied by his target bonus percentage. The resulting amount is then multiplied by the corporate performance percentage approved by the Compensation Committee, which is dependent on the achievement of corporate performance goals, and also potentially adjusted upwards or downwards for individual executives based on their individual contribution toward the corporate results during the relevant year and prorated for their time employed in 2016. For 2016, the Compensation Committee determined that our Named Executive Officers had achieved 90% of their corporate performance goals and individual contribution toward the corporate results. Key factors in determining the 2016 level of achievement included full enrollment of the LJPC-501 study, reporting positive phase 1 results for the LJPC-401 study, and the agreement with the European Medical Agency on the design of a pivotal trial for LJPC-401. Performance-based cash bonus payouts made to the Named Executive Officers in January 2017 for their performance in 2016 are shown in the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table.

For annual performance-based cash bonuses for our executive officers, in any given year, a minimum overall goal achievement of greater than or equal to 50% is required for an executive officer to earn any performance-based cash bonus. The target bonus can be earned if a goal achievement of 100% is obtained; for extraordinary performance in corporate goal achievement, up to 150% of the target bonus for that goal could be awarded. Accordingly, for the Named Executive Officers, there is the potential to receive up to 150% of their overall bonus target. The Compensation Committee retains broad discretion to modify our target goals at any time, including the methodology for calculating the specific bonus amounts. The Compensation Committee may also, in its sole discretion, determine to either increase annual incentive bonus payouts for extraordinary achievement or to reduce payout if economic and business conditions warrant.

Equity Compensation

The executive equity incentive compensation program is designed to promote high performance and achievement of corporate goals by employees on a long-term basis, encourage the growth of shareholder value and allow employees to participate in the long-term success of the Company. As of December 31, 2016, the Company had approximately 102 employees and four non-employee directors who are eligible to receive equity awards. Under the 2013 Equity Incentive Plan, the Board (or a committee thereof, including the Compensation Committee) may grant stock options, shares of stock, restricted stock units, stock appreciation rights and performance awards. In granting these awards, the Board (or a committee thereof, including the Compensation Committee) may establish any conditions or restrictions it deems appropriate.

To date, our Company has generally granted equity to our executive officers and other employees in the form of stock options. These awards will provide compensation only to the extent that the Company’s stock price appreciates over that time.


The Compensation Committee has provided the management team with an equity stake in the business, which we believe aligns the long-term interests of the management team with our shareholders. Because a financial gain from stock options is only possible if the price of the Common Stock has increased, the Company believes that option grants motivate our executives and other employees to deliver superior performance and focus on behaviors and initiatives that lead to long-term value creation, which benefitsdefined contribution plan (the “401(k) Plan”) covering substantially all of the Company’s shareholders.employees, including NEOs. The Company typically grants time-based vesting options, but has also granted performance-based stock and option awards to our Chief Executive Officer and also certain other executives upon occasion.

Stock option award levels are based on option grant guidelines approved by the Board or the Compensation Committee and vary among employees based on their level within the Company and their individual performance. Annual awards of stock options to executives are made as part of the annual review of executive performance, which typically occurs around year end. Newly hired or promoted executives receive their award of stock options on their date of hire/promotion or at the next regularly scheduled Compensation Committee or Board meeting following their hire or promotion date. The Compensation Committee targets stock option award levels for executives, including the Chief Executive Officer, at or near the 75th percentile of long-term incentive awards of executives with similar roles at similar organizations, based on broad comparative data. The resulting amount is then multiplied by the corporate performance percentage approved by the Compensation Committee, which is dependent on the achievement of corporate performance goals, and also potentially adjusted upwards or downwards for individual executives based on their individual contribution toward the corporate results during the relevant year and prorated for their time employed in 2016. The Compensation Committee, in line with the Company’s philosophy to encourage long-term value creation, elected to emphasize the equity portion of each executive’s overall total compensation. The grant of options by the Company is unrelated to any anticipated major announcements made by the Company and is thus not influenced by any material, non-public information that may exist at the time of grant.

Following an annual review of compensation, as well as individual and corporate performance that was completed in December 2016, Dr. Tidmarsh, Dr. Chawla, Mr. Mulroy and Ms. Carver were each granted an option to purchase up to 214,700, 64,100, 64,100 and 64,100 shares, respectively, of Common Stock at a price equal to the fair market value of Common Stock on the grant date, which was January 4, 2017. These options shall vest and become exercisable with respect to one-quarter of the underlying shares on the first anniversary of the grant date, and the remaining shares are to vest ratably each month thereafter over the next three years, such that these options are fully vested and exercisable on the fourth anniversary of the grant date, subject to the recipient’s continued service with the Company through each such vesting date. These options were granted and governed in all respects under the Company’s 2013 Equity Incentive Plan.

Employee Benefit Program

We have not historically provided special benefits or perquisites to our Named Executive Officers and did not do so in 2016. The Named Executive Officers are eligible to participate in all of the Company’s health, welfare, paid time-off and 401(k) retirement savings benefit programs on the same terms as are available to other employees. These benefit programs are designed to enable the Company to attract and retain its workforce in a competitive marketplace. Health, welfare and paid time-off benefits ensure that the Company has a productive and focused workforce through reliable and competitive health and other benefits. The retirement savings plan helps employees save and prepare financially for retirement.

The Company’s retirement savings plan (“401(k) Plan”) is a tax-qualified retirement savingssaving plan, pursuant to which all employees including the Named Executive Officers, are able to contribute the lesser of 50% of their annual compensation (as defined) or the limit prescribed by the Internal Revenue Service to the 401(k) Plan on a before-tax basis. The Company matches employee contributions to the 401(k) Plan based on each participant’s contribution during the plan year, up to 3.5% of each participant’s annual compensation.

Employment and Separation Arrangements

From time to time, we have provided executive officers with certain termination and change in control benefits. Where implemented, the Compensation Committee or Board has approved these termination and change in control benefits in order to maintain market-competitive compensation practices and to mitigate some of the risk that exists for executives working in a biopharmaceutical company at our current stage of development and where the possibility exists that we may be acquired if our business efforts succeed. These arrangements are intended to retain highly skilled executives who have, or who may seek, alternatives that may appear to them to be less risky in terms of the potential loss of their position following a merger or sale, particularly where the services of these executive officers may not be required by the acquirer.



A summary of the terms of the arrangements we have with our Named Executive Officers and the potential value of payments upon termination or change in control is provided in an amendment to the annual report on Form 10-K under the headings “Employment Agreements” and “Payments Upon Termination or Change in Control.”

Competitive Market Review

In 2016, the Compensation Committee retained B&B to assist the committee in identifying a selected peer group of companies within the biotechnology/biopharmaceutical industry and with similar identified characteristics to our Company to be used to assess compensation levels for the top senior management positions. B&B was involved with the process of selecting an appropriate peer group for our Company and in collecting and analyzing compensation data of the companies within our peer group. In addition, for some positions, we reviewed other broader market surveys within our industry. While we do not establish compensation levels based solely on comparative data, pay practices at other companies are an important factor that is considered in assessing the reasonableness of compensation and ensuring that our compensation practices are competitive in the marketplace. In compiling the peer group for 2016, the factors that were identified as providing well-defined comparatives to the Company were market capitalization ($400 million to $1 billion), current stage of clinical development or business activity (product(s) in Phase 2 and Phase 3 studies, and/or close to potential commercialization) and number of employees ( < 150). While the Compensation Committee reviewed compensation data pertaining to these companies, it determined that elements such as the Company’s diversity of clinical development activities and the level of executive experience should be significant factors in assessing compensation levels, and certain factors such as number of employees or market capitalization might allow for easy categorization, but were not necessarily the most significant factors in determining the relative need by the Company to recruit highly skilled executives. The 20 companies in the peer group identified by B&B for 2016 are listed below.
Agenus Inc.Ardelyx, Inc.
Array BioPharma Inc.Blueprint Medicines Corporation
Corcept Therapeutics IncorporatedEnanta Pharmaceuticals, Inc.
Epizyme, Inc.Flexion Therapeutics, Inc.
Insmed IncorporatedKeryx Biopharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc.Otonomy, Inc.
Raptor Pharmaceuticals Corp.Revance Therapeutics, Inc.
Sucampo Pharmaceuticals, Inc.Synergy Pharmaceuticals Inc.
TG Therapeutics, Inc.Vanda Pharmaceuticals Inc.
Xencor, Inc.Ziopharm Oncology, Inc.

Tax Considerations

Deductibility of Executive Compensation. In making compensation decisions affecting our executive officers, the Board or the Compensation Committee may, among other considerations, also give consideration to our ability to deduct, under applicable federal corporate income tax laws, compensation payments made to executives. Specifically, the Compensation Committee or the Board may consider the requirements and impact of Section 162(m) of the Internal Revenue Code, which limits the tax deductibility to us of compensation in excess of $1.0 million in any year for certain executive officers, except for qualified “performance-based compensation” under the Section 162(m) rules. Although the Compensation Committee or the Board may consider the Section 162(m) rules as a factor in determining compensation, these considerations will not necessarily limit compensation to amounts deductible under Section 162(m). In addition, the rules promulgated under Section 162(m) are complicated, and may change from time to time, sometimes with retroactive effect. As such, it cannot be guaranteed that any amounts intended to qualify as exempt “performance-based compensation” under Section 162(m) will so qualify.

Minimum Stock Ownership Requirements

There are no minimum stock ownership guidelines for our executives or employees, although senior members of our management team are encouraged and expected to have a significant direct interest in the value of our Common Stock through the receipt of equity awards and/or open market purchases, as the case may be. We strive to design our compensation program to stress long-term ownership in Company equity as the means of best aligning the interests of our executives with those of our shareholders.



Compensation Committee Report

The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K. Based on this review and discussion, the Compensation Committee recommended that the foregoing Compensation Discussion and Analysis be included in this proxy statement.

Submitted by the Compensation Committee

Craig A. Johnson, Chairman    
Laura L. Douglass

Summary Compensation Table

The following tables and descriptive materials set forth information concerning compensation earned for services rendered to us by our Named Executive Officers during 2016, 2015 and 2014.
Name and Principal Position Year Salary 
Options
Awards(1)
 
Non-Equity
Incentive Plan
Compensation(2)
 
All Other
Compensation(3)
 Total
George F. Tidmarsh, M.D., Ph.D., President, Chief Executive Officer and Secretary 2016 $557,000
 $3,827,488
 $251,000
 $18,148
 $4,653,636
  2015 $525,000
 $14,871,700
 $223,000
 $18,228
 $15,637,928
  2014 $470,000
 $1,936,979
 $235,000
 $63,930
 $2,705,909
Lakhmir S. Chawla, M.D., Chief Medical Officer(4)
 2016 $411,500
 $1,142,585
 $132,000
 $40,938
 $1,727,023
  2015 $190,000
 $5,190,689
 $119,000
 $52,588
 $5,552,277
Dennis M. Mulroy, Chief Financial Officer(5)
 2016 $340,000
 $1,142,714
 $110,000
 $17,984
 $1,610,698
  2015 $236,513
 $2,172,844
 $72,000
 $9,376
 $2,490,733
Jennifer A. Carver, Chief Operating Officer(6)
 2016 $320,000
 $1,142,714
 $107,000
 $55,381
 $1,625,095

1.This column represents the net aggregate grant date fair value, computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Topic 718, for all stock options and other equity awards granted. The 2016 options include options awarded in January 2017 for 2016 performance. The 2015 options, include options awarded in February 2015 for 2014 performance, options awarded in December 2015 for 2015 performance, new hire options awarded in 2015 and other options awarded in 2015. The assumptions used in calculating the fair value of the stock options and awards can be found under Note 6 to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2016. These amounts reflect the net grant date fair value for these stock options and awards and do not necessarily correspond to the actual value that will be realized by the Named Executive Officer.
2.The amounts listed represent cash awards earned for the year under the Company’s bonus program.
3.The amounts in the column represent the Company’s contribution to the 401(k) plan, life issuance premiums paid by the Company, a housing allowance for Dr. Chawla and travel and housing expenses for Ms. Carver. For 2016, the amounts include (a) the Company’s contribution to the 401(k) plan for Dr. Tidmarsh, Dr. Chawla, Mr. Mulroy and Ms. Carver in the amount of $15,826, $15,128, $14,420 and $7,023, respectively (b) life insurance premiums paid by the Company for Dr. Tidmarsh, Dr. Chawla, Mr. Mulroy and Ms. Carver in the amount of $2,322, $810, $3,564 and $3,564, respectively (c) $25,000 housing allowance for Dr. Chawla and (d) $44,794 for travel and housing expenses for Ms. Carver.
For 2015, the amounts include the Company contributions to the 401(k) plans for Dr. Tidmarsh, Dr. Chawla and Mr. Mulroy in the amount of $15,806, $4,750 and $7,000, respectively, and life insurance premiums paid by the Company for Dr. Tidmarsh, Dr. Chawla and Mr. Mulroy in the amount of $2,422, $338 and $2,376, respectively. In addition, Dr. Chawla received relocation expenses covered by the Company in the amount of $47,500.


4.Dr. Chawla joined the Company in July 2015 with an initial annual salary of $380,000.
5.Mr. Mulroy joined the Company in April 2015 with an initial annual salary of $320,000.
6.Ms. Carver became a Named Executive Officer of the Company in January 2016 with an initial annual salary of $300,000.

Grants of Plan-Based Awards Table

The following table sets forth certain information regarding grants of plan-based awards for performance in calendar year 2016.
 Name 
Grant
Date
 
All Other Option Awards: Number of Securities Underlying Options(#)(1)
 Exercise Price of Option Awards ($/Sh) 
Grant Date Fair Value of Option Awards(2)
 
 George F. Tidmarsh, M.D., Ph.D. 1/4/2017 214,700 $19.19
 $3,827,488
 Lakhmir S. Chawla, M.D. 1/4/2017 64,100 $19.19
 $1,142,585
 Dennis M. Mulroy 1/4/2017 64,100 $19.19
 $1,142,585
 Jennifer A. Carver 1/4/2017 64,100 $19.19
 $1,142,585
1.These options were awarded in January 2017 for performance in calendar year 2016.
2.This column reflects the aggregate grant date fair value of equity awards granted in 2017 and calculated in accordance with FASB ASC 718. The assumptions used in calculating the fair value of the stock options and awards can be found under Note 6 to the Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2016.



Outstanding Equity Awards at 2016 Year End
  Option Awards Stock Awards
Name Number of Securities Underlying Unexercised Options (#) Exercisable Number of Securities Underlying Unexercised Options (#) Unexercisable 
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options(2)
 
Option
Exercise
Price ($)
 
Option
Expiration
Date(1)
 Number of Unearned Shares, Units or Other Rights that have not Vested (#) Market or Payout Value of Unearned Shares, Units or Other Rights that have not Vested($)
George F. Tidmarsh, M.D., Ph.D. 113,128
 67,872
(3)— $10.84
 4/3/2024 — —
  131,250
 168,750
(3)— $19.69
 2/23/2025 — —
  — — 30,000
(2)$35.58
 8/31/2025 — —
  72,251
 216,749
(4)— $28.24
 12/21/2025 — —
  — 214,700
(4)— $19.19
 1/4/2027 — —
  — — — — — 542,679
 $9,513,163
Lakhmir S. Chawla, M.D. 41,250
 18,750
(5)— $17.34
 2/6/2025 — —
  20,000
 40,000
(6)— $35.58
 8/31/2025 — —
  — — 30,000
(2)$35.58
 8/31/2025 — —
  14,676
 44,024
(4)— $28.24
 12/21/2025 — —
  — 64,100
(4)— $19.19
 1/4/2027 — —
Dennis M. Mulroy 25,000
 35,000
(4)— $18.23
 4/6/2025 — —
  10,376
 31,124
(4)— $28.24
 12/21/2025 — —
  — 64,100
(4)— $19.19
 1/4/2017 — —
Jennifer A. Carver 12,375
 5,625
(3)— $7.26
 2/7/2024 — —
  6,250
 3,750
(3)— $7.69
 5/22/2024 — —
  6,250
 5,750
(4)— $19.8
 1/9/2025 — —
  10,776
 12,724
(4)— $19.69
 2/23/2025 — —
  — — 15,000
(2)$35.58
 8/31/2025 — —
  12,751
 38,249
(4)— $28.24
 12/21/2025 — —
  — 64,100
(4)— $19.19
 1/4/2027 — —
1.All stock options expire ten years from the date of grant.
2.Equity incentive plan awards consist of performance-based stock options. The number of shares issuable were vested at 75% based on the achievement of patient enrollment related to the Phase 3 clinical trial for the LJPC-501 program, by certain target dates.
3.The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vests and becomes exercisable ratably on a quarterly basis over the next three years.
4.The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
5.The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the date of grant and then vests and becomes exercisable ratably on a quarterly basis over the next three years.
6.The stock option vests and becomes exercisable with respect to the underlying shares ratably on a monthly basis over four years after the grant date.



Option Exercises and Stock Vested in 2016
  Stock Awards
Name Number of Shares
Acquired on Vesting (#)		 
Value Realized
on Vesting ($)
George F. Tidmarsh, M.D., Ph.D. 500,000
 $1,452,120
Lakhmir S. Chawla, M.D. —
 —
Dennis M. Mulroy —
 —
Jennifer A. Carver —
 —

Pension Benefits

We do not maintain any pension benefits.

Non-qualified Defined Contribution and Other Non-qualified Deferred Compensation Plans
We do not maintain a defined benefit pension plan or a non-qualified deferred compensation plan.

Potential Payments upon Termination or Change in Control
The following table sets forth information regarding potential payments that would have been made to our Named Executive Officers upon various termination or change in control events assuming such events occurred as of December 31, 2016. Because none of our Named Executive Officers have employment agreements that provide for severance payments on a termination without cause or a resignation for good reason, no such potential payments are reported in the table below.


Name 
Without Cause or
With Good Reason
 Without Cause or With Good Reason Within Three Months Before or 12 Months After a Change in Control
George F. Tidmarsh, M.D., Ph.D.    
Severance(1)
 $—
 $—
Benefit continuation —
 —
Accelerated vesting of stock awards(2)
 —
 454,064
Total $—
 $454,064
Lakhmir S. Chawla, M.D.    
Severance(1)
 $—
 $—
Benefit continuation —
 —
Accelerated vesting of stock awards(2)
 —
 3,563
Total $—
 $3,563
Dennis M. Mulroy    
Severance(1)
 $—
 $—
Benefit continuation —
 —
Accelerated vesting of stock awards(2)
 —
 —
Total $—
 $—
Jennifer A. Carver    
Severance(1)
 $—
 $—
Benefit continuation —
 —
Accelerated vesting of stock awards(2)
 —
 94,669
Total $—
 $94,669
1.The executive officers' employment offer letters do not provide for severance benefits upon termination, with or without a change of control. However, pursuant to the terms of the stock options and equity awards, the executive officers, are entitled to accelerated vesting of their equity awards in certain circumstances, as set forth in this table.
2.Represents the value of in-the-money, unvested equity awards that would have accelerated if the Named Executive Officers were terminated on December 31, 2016, based on the closing price of our Common Stock of $17.53 on December 31, 2016.

Director Compensation

Retainers and Fees for 2016Retainer Fees.. Directors who are also our employees receive no extra compensation for their service on the Board. In 2016,For the year ended December 31, 2019, our non-employee directors received an annual fee of $60,000 and the Chair of the Audit Committee received an additional annual fee of $15,000, both of which iswere paid quarterly. The Chairman of the Board, Mr. Tang, has elected to waive all cash compensation for his service as a director.

Option Grants for 2016Grants.. Each of our non-employee directors is eligible to receive, uponon becoming a non-employee director, a one-time grant of a non-qualified stock option under the Company’s 2013 Equity Incentive Plan in an amount to be determined by the Board at an exercise price equal to the fair market value of a share of Common Stockcommon stock on the date of grant.grant date. These non-employee director options have a term of 10 years and vest with respect to 1/3rdone-third of the underlying shares on the one-year anniversary of the grant and with respect to the remainder of the underlying shares on a quarterly basis for two years thereafter. Each non-employee director receives an additional grant annually of a non-qualified stock option in an amount to be determined by the Board. These non-employee director options have a term of 10 years and vest fully on the one-year anniversary of the grant.grant date. The exercise price for these additional non-employee director options is the fair market value of our Common Stockthe common stock on the date of their grant.grant date. All outstanding non-employee director options vest in full immediately prior to any change in control. Each non-employee director is also eligible to receive additional options under the Company’s 2013 Equity Incentive Plan at the discretion of the Board. These options vest and become exercisable pursuant to the Company’s 2013 Equity Incentive Plan and the terms of the option grant.



For their serviceThe following table shows the compensation earned in 2016, each2019 by the non-employee director was awarded, in January 2017 an option to purchase up to 10,000 shares of Common Stock at $19.19 per share, a price per share equal to the fair value of our Common Stockdirectors who served on the date of grant. The table below sets forthBoard during the total compensation paid to our non-employee directors for 2016.
year ended December 31, 2019:
Name 
Fees Earned or
Paid in Cash
 
Stock
Awards
 
Options
Awarded(1)(2)
 Total
Kevin C. Tang(1)
 —
 — $175,362
 $175,362
Laura L. Douglass $60,000
 — $175,362
 $235,362
Craig A. Johnson $60,000
 — $175,362
 $235,362
Robert H. Rosen $60,000
 — $175,362
 $235,362
Name 
Fees Earned or
Paid in Cash
 
Option
Awards(1)
 Total
Kevin Tang(2)
 $—
 $34,407
 $34,407
Craig Johnson $75,000
 $34,407
 $109,407
Laura Johnson $60,000
 $34,407
 $94,407
David Ramsay(3)
 $15,000
 $139,647
 $154,647
Robert Rosen $60,000
 $34,407
 $94,407
1.(1)The amounts reported in this column reflect the grant-date fair values of stock options granted to each director in January 2020 for services rendered in 2019, calculated in accordance with FASB ASC Topic 718, Compensation-Stock Compensation. For a discussion of the assumptions used to calculate the value of our stock options, see Note 6 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019. Each non-employee director was granted an option to purchase up to 12,000 shares of common stock at $3.93 per share, the fair value of the common stock on the grant date. As of December 31, 2019, the aggregate number of option awards outstanding for Kevin Tang, Craig Johnson, Laura Johnson, David Ramsay and Robert Rosen were 82,000, 101,000, 90,500, 30,000 and 82,000, respectively.
(2)Mr. Tang has elected to waive all cash compensation for his service as a director.
2.(3)IncludedOn becoming a non-employee director of the Company in this table isOctober 2019, Mr. Ramsay was granted an option to purchase up to 18,000 shares of common stock at $8.43 per share, the estimated fair value of awards made in January 2017 relating to 2016 service.the common stock on the grant date.

Certain Relationships and Related-Party Transactions

Pursuant to our Code of Ethics, our executive officers, directors and employees must disclose transactions involving actual or apparent conflicts of interest, such as related-party transactions, to the Chairperson of the Audit Committee. Additionally, the Audit Committee is responsible for review and approval of all related-party transactions in which any officer, director or shareholder has a direct or indirect interest and would be required to be disclosed under Item 404(a) of SEC Regulation S-K, and has written policies and procedures for reviewing, approving or ratifying any transaction required to be reported under Item 404(a) of SEC Regulation S-K. In reviewing related-party transactions, the Audit Committee evaluates any transaction in which a “related person” (as defined in Item 404(a) of SEC Regulation S-K) was or is to be a participant and the amount involved exceeds $120,000, and in which the related person had or will have a direct or indirect material interest. The Audit Committee also will consider whether the proposed terms are at least as favorable to the Company as could be obtained from unaffiliated third parties and will confirm that there is a bona fide business purpose for the transaction.

During the year ended December 31, 2015, the Company entered into a services agreement with a third party that is controlled by investment funds affiliated with the Chairman of the Company’s Board. Pursuant to the services agreement, the Company provides certain services to this related party, including, but not limited to, research and development and clinical trial design and management for the project undertaken. In exchange for providing such services, the Company receives payments at a negotiated, arms-length rate that has been reviewed and approved by the Company’s Audit Committee. As a result, the consideration received by the Company for its services is considered to be no less favorable to the Company than comparable terms that the Company could obtain from an unaffiliated third party in an arms-length transaction. The services agreement may be canceled by either party upon 60-days’ written notice to the other party.

During the year ended December 31, 2016, the Company recognized approximately $616,000 of contract revenue for services and costs provided under the services agreement.

In addition, the Company and the Company’s Chief Executive Officer hold a non-voting profit interest in the related party, which provides the potential to receive a portion of the future distributions of profits, if any, that may be distributed by the third party entity.



Equity Compensation Plan Information

The following table provides information as of December 31, 2016 with respect to shares of our Common Stock that may be issued under our equity compensation plans.
Plan Category Number of Securities to Be Issued upon Exercise of Outstanding Options, Warrants and Rights (a) Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights (b) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c)
Equity compensation plans approved by security holders 2,567,462
(1)$21.14
 1,960,200
Equity compensation plans not approved by security holders 60,000
 $18.23
 —
Total 2,627,462
 $21.07
 1,960,200
1.Outstanding options to purchase shares of our Common Stock under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan.




SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding beneficial ownership of our Common Stockshares of common stock as of JulyMarch 1, 2017, based on information available to us and filings with the SEC by:2020 for:
Each of our directors;
Each of our Named Executive Officers;
All of our current directors and executive officers as a group; and
Each personseach shareholder or group of affiliated personsshareholders known by us to be athe beneficial owner of more than 5% of our Common Stock.outstanding shares of common stock;

each of our directors;
each of our NEOs; and
all of our directors and executive officers as a group.
Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares of stock. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, shares of common stock issuable under stock options that are exercisable within 60 days of JulyMarch 1, 20172020 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person.



Unless otherwise indicated and subject to applicable community property laws, to our knowledge, each shareholder named in the following table possesses sole voting and investment power over his, her or its shares of Common Stock,common stock, except for those jointly owned with that person’s spouse. Percentage of beneficial ownership of Common Stockcommon stock is based on 22,123,45627,263,911 shares of Common Stockcommon stock outstanding as of JulyMarch 1, 2017.2020. Unless otherwise noted below, the address of each person listed on the table is c/o La Jolla Pharmaceutical Company, 10182 Telesis4550 Towne Centre Court, 6th Floor, San Diego, California 92121.
Name and Address 
Shares of Common Stock Owned(1)
 Shares with Right to Acquire Within 60 Days Total Beneficial Ownership Percentage of Common Stock
Greater than 5% Shareholders        
  Tang Capital Partners, LP(2)
 3,440,419
 —
 3,440,419
 15.55%
  FMR LLC(3)
 2,738,101
 —
 2,738,101
 12.38%
  Broadfin Capital, LLC(4)
 1,510,316
 —
 1,510,316
 6.83%
  RTW Investments, LLC(5)
 1,086,037
 263,029
 1,349,066
 6.03%
  Perceptive Advisors LLC(6)
 1,319,274
 —
 1,319,274
 5.96%
  Janus Capital Management LLC(7)
 1,140,139
 —
 1,140,139
 5.15%
         
Directors and Executive Officers        
  Kevin C. Tang(2)
 3,440,419
 38,000
 3,478,419
 15.70%
  George F. Tidmarsh, M.D., Ph.D. 1,376,086
 484,981
 1,861,067
 8.04%
  Lakhmir S. Chawla, M.D. 2,085
 135,708
 137,793
 *
  Laura L. Douglass —
 56,250
 56,250
 *
  Craig A. Johnson —
 56,250
 56,250
 *
  Robert H. Rosen —
 38,000
 38,000
 *
  Dennis M. Mulroy 500
 52,292
 52,792
 *
  Jennifer A. Carver 3,500
 83,071
 86,571
 *
  James M. Rolke 73,328
 46,577
 119,905
 *
All Directors and Executive Officers as a group 4,895,918
 991,129
 5,887,047
 25.47%
Name and Address of Beneficial Owner 
Number of Shares
Beneficially Owned(1)
 
Percentage of
Shares Beneficially Owned
Greater than 5% Shareholders    
Tang Capital Partners, LP(2)
 8,080,345
 29.64%
  Broadfin Capital, LLC(3)
 2,688,068
 9.86%
  RTW Investments, LP(4)
 2,551,020
 9.36%
BlackRock, Inc.(5)
 1,574,336
 5.77%
  Venrock Healthcare Capital Partners II, L.P. (6)
 1,375,000
 5.04%
     
Directors and Named Executive Officers    
  Kevin Tang(2)
 8,390,345
 30.70%
  Lakhmir Chawla, M.D.(7)
 318,102
 1.15%
  Dennis Mulroy(8)
 207,817
 *
  Craig Johnson(9)
 89,000
 *
  Laura Johnson(10)
 79,000
 *
  Robert Rosen(11)
 70,000
 *
  Darryl Wellinghoff(12)
 30,318
 *
  David Ramsay —
 *
All directors and executive officers as a group (9 persons) 9,446,358
 33.39%

* Represents beneficial ownership of less than one percent (1%).percent.

1.(1)Shares of Common Stock owned are based uponBased on the Company’s review of Statement of Beneficial Ownership Filings with the SEC on Schedules 13D, 13D/A, 13G, 13G/A or Form 4, and 13G/A; and unless otherwise indicated, does not include any shares purchased as part ofother information included in the Common Stock offering in March 2017.Company’s records. Shares of Common Stockcommon stock owned can vary since the date of such filings.
2.(2)
Based uponon a Form 4 filed with the SEC on February 3, 2020 and a Schedule 13D/A filed with the SEC on March 6, 2017.January 14, 2020. The Form 4 and the Schedule 13D/A waswere filed jointly filed by Tang Capital Partners, LP, Tang Capital Management, LLC and Kevin C. Tang. Mr. Tang is the Chairman of the Board. Tang Capital Partners, LP shares voting and dispositive power over such shares with Tang Capital Management, LLC and Kevin Tang. The shares of Common Stockcommon stock owned and beneficially owned by Mr. Tang include shares of Common Stockcommon stock owned by Tang Capital Partners, LP and other shares of Common Stockcommon stock for which Mr. Tang shares voting and/or dispositive power. Mr. Tang has sole voting and dispositive power over 38,00070,000 shares underlying stock options that were exercisable within 60 days of JulyMarch 1, 2017.2020. The


beneficial ownership for Tang Capital Partners, LP and Mr. Tang excludes approximately 6,067,784 and 6,338,500 shares of common stock, respectively, that are potentially issuable on conversion of the Company’s Series C-12 Convertible Preferred Stock. The shares of Series C-12 Convertible Preferred Stock have a limit on the ability of the holder to convert, to the extent that the holder would beneficially own greater than 9.999% of shares of the Company’s common stock following such conversion, provided that the holder has the ability to waive, increase or decrease this limitation on conversion on providing the Company with 61 days of prior written notice. The address of the foregoing entities and person is 4747 Executive Drive, Suite 510, San Diego, CA 92121.
(3)Based on a Schedule 13G/A filed with the SEC on February 13, 2020. The Schedule 13G/A was filed jointly by Broadfin Capital, Partners, LPLLC, Broadfin Healthcare Master Fund, Ltd. and Mr. Tang excludes approximately 6,067,784 shares of Common Stock that are potentially issuable upon conversion of shares of the Company’s Series C-12 Convertible Preferred Stock. Mr. Tang’s beneficial ownership excludes an additional approximately 270,716 shares of Common Stock that are potentially issuable upon conversion of shares of the Company’s Series C-12 Convertible Preferred Stock. The shares of Series C-12 Convertible Preferred Stock have a limit on the ability of the holderKevin Kotler (collectively, “Broadfin”). Broadfin reports it has shared voting and dispositive power with respect to convert, to the extent that the holder would beneficially own greater than 9.999% of the Common Stock following such conversion, provided that the holder has the ability to waive, increase or decrease this limitation on conversion upon providing the Company with 61 days of prior written notice. The beneficial ownership for Tang Capital Partners, LP, includes 149,254 shares of Common Stock purchased in the Common Stock offering in March 2017. Mr. Tang disclaims beneficial ownership of all shares reported herein except to the extent of his pecuniary interest therein.2,688,068 shares. The address of the foregoing entitiesBroadfin Capital, LLC and personKevin Kotler is 4747 Executive Drive, Suite 510, San Diego, CA 92121. Mr. Tang300 Park Avenue, 25th Floor, New York, NY 10022. The address of Broadfin Healthcare Master Fund, Ltd. is the Chairman of the Board.20 Genesis Close, Ansbacher House, Second Floor, P.O. Box 1344, Grand Cayman KY1-1108, Cayman Islands.
3.(4)
Based uponon a Schedule 13G/A filed with the SEC on February 14, 2017.2020. The Schedule 13G/A was filed jointly by FMR LLC, Abigail P. Johnson and Select Biotechnology Portfolio. FMR LLC reports it has no sole voting power and


has sole dispositive power with respect to 2,738,101 shares. The address of the entities and persons is 245 Summer Street, Boston, MA 02210.
4.Based upon a Schedule 13G filed with the SEC on February 10, 2017. The Schedule 13G was jointly filed by Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler. Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler share voting and dispositive power over such shares. The address of the forgoing entities and person is 300 Park Avenue, 25th Floor, New York, NY 10022.
5.
Based upon a Schedule 13G filed with the SEC on February 22, 2017. The Schedule 13G was jointly filed by RTW Investments, LP, RTW Master Fund, Ltd. and Roderick Wong. RTW Investments, LP shareis the investment manager of RTW Master Fund, Ltd. and one or more private funds, and shares voting and dispositive power over such shares. RTW Investments, LP and Roderick Wong report that they have shared voting and dispositive power with respect to 2,551,020 shares. RTW Master Fund, Ltd reports that it has shared voting and dispositive power with respect to 1,857,707 shares. The beneficial ownership for RTW Investments, LLCLP includes approximately 263,029 shares of Common Stockcommon stock that are potentially issuable uponon conversion of shares of the Company’s Series C-12 Convertible Preferred Stock. The address of the foregoing entitiesRTW Investments, LP and personRoderick Wong is 250412 West 55th15th Street, 16th9th Floor, Suite A, New York, NY 10019.10011. The address of RTW Master Fund, Ltd. is 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands.
6.(5)Based uponon a Schedule 13G/A filed with the SEC on February 5, 2020. BlackRock, Inc. reports it has sole voting power with respect to 1,549,190 shares and sole dispositive power with respect to 1,574,336 shares. The address of the foregoing entity is 55 East 52nd Street, New York, NY 10055.
(6)Based on a Schedule 13G filed with the SEC on February 14, 2017.11, 2019. The Schedule 13G was filed jointly filed by Perceptive AdvisorsVenrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Joseph EdelmanVenrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Perceptive Life Sciences master Fund, Ltd. Perceptive AdvisorsBong Koh (collectively, “Venrock”). The Schedule 13G reports that the 1,375,000 shares are owned directly as follows: 264,300 shares are owned by Venrock Healthcare Capital Partners II, L.P.; 107,100 shares are owned by VHCP Co-Investment Holdings II, LLC; 912,414 shares are owned by Venrock Healthcare Capital Partners III, L.P.; and 91,186 shares are owned by VHCP Co-Investment Holdings III, LLC. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. Messrs. Shah and Koh are the managing members of VHCP Management II, LLC and Joseph Edelman shareVHCP Management III, LLC. Venrock reports it has shared voting and dispositive power over suchwith respect to 1,375,000 shares. The address of the forgoingforegoing entities and personpersons is 51 Astor Place, 10th7 Bryant Park, 23rd Floor, New York, NY 10003.10018.
7.(7)Based upon a Schedule 13G filed with the SEC on February 13, 2017. Janus Capital Management LLC has sole votingConsists of 8,109 shares of common stock and sole dispositive power over such shares. The address309,993 shares of the forgoing entities and person is 151 Detroit Street, Denver, CO 80206.common stock underlying stock options exercisable by Dr. Chawla within 60 days of March 1, 2020.
(8)Consists of 4,818 shares of common stock and 202,999 shares of common stock underlying stock options exercisable by Mr. Mulroy within 60 days of March 1, 2020.
(9)Consists of 89,000 shares of common stock underlying stock options exercisable by Mr. Johnson within 60 days of March 1, 2020.
(10)Consists of 500 shares of common stock and 78,500 shares of common stock underlying stock options exercisable by Ms. Johnson within 60 days of March 1, 2020.
(11)Consists of 70,000 shares of common stock underlying stock options exercisable by Mr. Rosen within 60 days of March 1, 2020.
(12)Consists of 8,528 shares of common stock and 21,790 shares of common stock underlying stock options exercisable by Mr. Wellinghoff within 60 days of March 1, 2020.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities.

To our knowledge, based solely on our review of Forms 3, 4 and 5 filed with the SEC or written representations that no Form 5 was required, during the year ended December 31, 2019, our directors, executive officers and persons who beneficially own more than 10% of a registered class of our equity securities timely filed all reports required under Section 16(a) of the Exchange Act, except for one Form 4 for each of Dr. Chawla, Mr. Johnson, Mr. Mulroy, Mr. Rolke and Mr. Wellinghoff that were inadvertently filed 1 day late to report one transaction.



OTHER INFORMATIONEquity Compensation Plan Information

The following table provides certain information regarding our equity compensation plans in effect as of December 31, 2019:
Plan Category 
Number of Securities to Be Issued
upon Exercise of Outstanding
Options, Warrants and Rights
(1)
 
Weighted-average
Exercise Price of Outstanding
Options, Warrants
and Rights
(2)
 
Number of Securities
Remaining Available for Future Issuance under
Equity Compensation
Plans, excluding
Securities Reflected in Column (1)
(3)
Equity compensation plans approved by security holders:      
2013 Equity Incentive Plan 5,476,840
 $19.70
 3,769,824
2018 Employee Stock Purchase Plan —
 $—
 568,728
Equity compensation plans not approved by security holders 140,000
 $11.81
 —
Total 5,616,840
 $19.50
 4,338,552

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Pursuant to our Code of Ethics, our directors, executive officers and employees must disclose transactions involving actual or apparent conflicts of interest, such as related party transactions, to the Chairperson of the Audit Committee. Additionally, the Audit Committee is responsible for review and approval of all related party transactions in which any officer, director or shareholder has a direct or indirect interest and would be required to be disclosed under Item 404(a) of Regulation S-K, and has written policies and procedures for reviewing, approving or ratifying any transaction required to be reported under Item 404(a) of Regulation S-K. In reviewing related party transactions, the Audit Committee evaluates any transaction in which a “related person” (as defined in Item 404(a) of Regulation S-K) was, or is to be, a participant and the amount involved exceeds the threshold specified by SEC rules (generally $120,000), and in which the related person had, or will have, a direct or indirect material interest. The Audit Committee also will consider whether the proposed terms are at least as favorable to the Company as could be obtained from unaffiliated third parties and will confirm that there is a bona fide business purpose for the transaction.

The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. In the fourth quarter of 2019, the Company received distributions of $1.9 million in connection with this profits interest.

Since January 1, 2018, there were no other transactions, and there are no currently proposed transactions, between the Company and any “related person” where the amount exceeded or will exceed $120,000, and in which any “related person” had or will have a direct or indirect material interest, other than compensation arrangements described elsewhere in this Proxy Statement.

OTHER MATTERS
Other Business

We know of no other business to be presented at the Annual Meeting. If any other business were to properly come before the Annual Meeting, it is intended that the shares represented by proxies would be voted with respect thereto in accordance with the best judgment of the persons named in the accompanying form of proxy.proxy card or voting instruction form.

Shareholder Proposals



Shareholders who wish to have proposals considered for inclusion in the proxy statementProxy Statement and form of proxy for our 20182021 Annual Meeting including nominees for directors, must cause their proposals to be received in writing by our Secretary at the address set forth on the first page of this proxy statement4550 Towne Centre Court, San Diego, California, 92121 no later than March 31, 2018,January 6, 2021, provided that if the Company moves the date of the 20182021 Annual Meeting of Shareholders by more than 30 days from the anniversary date of the Annual Meeting, then the deadline for submission of proposals will be a “reasonable time” before the Company begins to print and send its proxy materials for the 20182021 Annual Meeting of Shareholders (as defined in Rule 14a-8 under the Securities Exchange Act of 1934)Act). Any proposal should be addressed to our Secretary and may be included in next year’s proxy materials only if such proposal complies with our Bylaws, as discussed above,below, and the rules and regulations promulgated by the SEC. Nothing in this section shall be deemed to require us to include in our proxy statement or our proxy relating to any annual meetingProxy Statement any shareholder proposal or nomination that does not meet all of the requirements for inclusion established by the SEC. Submission of a shareholder proposal does not guarantee that it will be included in our Proxy Statement and form of proxy.

Further, our Bylaws require that a shareholder give our Secretary timely written notice of any proposal or nomination of a director.director to be brought before the annual meeting, but not included in the Proxy Statement and form of proxy. To be timely, such written notice must be received bydelivered to our Secretary not less than 90 days nor more than 120 days prior to a scheduled annual meeting of shareholders, or if less than 95 days’ notice or prior public disclosure of the date of the scheduled annual meeting of shareholders is given or made, such written notice must be received by our Secretary not later than the close of business on the seventh day following the earlier of the date of the first public announcement of the date of such meeting or the date on which such notice of the scheduled meeting was mailed.

Any notice to our Secretary regarding a shareholder proposal must include, as to each matter the shareholder proposes to bring before the meeting:Annual Meeting: (i) a brief description of the business desired to be brought before the meetingAnnual Meeting and the reasons for conducting such business at the meeting;Annual Meeting; (ii) the name and address, as they appear on our books, of the shareholder proposing such business and any shareholders known by such shareholder to be supporting such proposal; (iii) the class and number of shares of our stock that are beneficially owned by the shareholder and by any other shareholder known by such shareholder to be supporting such matter on the date of such shareholder notice; and (iv) any material interest of the shareholder in such business.

Any notice to our Secretary regarding a nomination for the election of a director must include: (i) the name and address of the shareholder who intends to make the nomination; (ii) the name and address of the person or persons to be nominated; (iii) the class and number of shares of our stock that are beneficially owned by the shareholder; (iv) a representation that such shareholder intends to appear in personbe present via live webcast or by proxy at the annual meeting and nominate the person or persons specified in the notice; (v) a description of all arrangements or understandings between the shareholder and each director nominee and any other person or persons (naming such persons)person(s)) pursuant to which the nomination or nominations are to be made by the shareholder; (vi) such other information regarding each director nominee as would be required to be included in a proxy statement filed pursuant to the proxy rules of the SEC had the director nominee been nominated, or intended to be nominated, by the Board; and (vii) the consent of each director nominee to serve as a director if so elected.

Incorporation by Reference

The reportReport of the audit committeeAudit Committee shall not be deemed to be soliciting material or to be filed with the SEC under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 or incorporated by reference in any document so filed.

Householding

The Company may satisfyWe have adopted a procedure approved by the SEC rules regardingcalled “householding.” Under this procedure, certain stockholders of record who have the same address and do not participate in electronic delivery of proxy materials includingwill receive only one copy of the proxy statement, annual reportmaterials, including this Proxy Statement, the Notice of the 2020 Annual Meeting of Shareholders, the 2019 Annual Report and notice to shareholders, by delivering a single notice to shareholders and, if applicable, a single set ofthe proxy materials to an address shared by twocard or voting instruction form, until such time as one or more Company shareholders. Some banks, brokers and other intermediaries may be participating in this practice of “householding” proxy statements and annual reports. This rule benefits both the Company and its shareholders as it reduces the volume of duplicate information received at a shareholder’s house and helps reduce the Company’s expenses. Each shareholder, however, will continuethese stockholders notifies us that they wish to receive individual proxy cards or voting instruction forms.copies. This procedure will reduce duplicate mailings and save printing costs and postage fees, as well as natural resources.



Shareholders who have previouslyIf you received a single set of disclosure documents may request their own copy“householding” mailing this year or in future years by contacting their bank, broker or other nominee record holder. The Company will also deliverand would like to have additional copies of the proxy materials mailed to you, please send a separate copy of this proxy statement to any shareholder upon written request to our Secretary at La Jolla Pharmaceutical Company, 10182 Telesis4550 Towne Centre Court, 6th Floor, San Diego, California 92121, Attn: George Tidmarsh, or upon oralcall (858) 207-4264, and we will promptly deliver the proxy materials to you. You may also submit a request by calling (858) 207-4264.

Similarly, shareholders who have previouslyto the aforementioned address or phone number if you received multiple copies of disclosure documents may writethe proxy materials and would prefer to the address or call the phone number listed above to request delivery ofreceive a single copy of these materials in the future.future, or if you would like to opt out of “householding” for future mailings.

Availability of Additional Information

Along with this proxy statement,Proxy Statement, we have provided each shareholder entitled to voteof record a copy of our 2019 Annual Report on Form 10-K for our year ended December 31, 2016, including all amendments thereto.Report. We will provide, withoutfree of charge, a copy of our Annual Report on Form 10-K for the year ended December 31, 2016,2019, including all amendments thereto, uponexhibits, on the written or oral request of any shareholder or beneficial owner of our Common Stock.common stock. Written requests should be directedPlease send a written request to the following address: Investor Relations,our Secretary at La Jolla Pharmaceutical Company, 10182 Telesis4550 Towne Centre Court, 6th Floor, San Diego, California 92121. Telephonic requests should be directed to92121 or call (858) 207-4264.

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street N.E., Washington, D.C. 20549-2521. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-732-0330. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may also find the materials we file with the SEC on the “Investor Relations” section of our website at www.ljpc.com. Information on our website is not incorporated by reference into, or made a part of, this proxy statement.

BY ORDER OF THE BOARD OF DIRECTORSBy Order of the Board of Directors,
 
/s/ George F. TidmarshDennis Mulroy
George F. Tidmarsh, M.D., Ph.D.Dennis Mulroy
President, Chief Financial Officer, Principal Executive Officer and Secretary

July 31, 2017April 29, 2020
San Diego, California



Appendix A

2013 Equity Incentive Plan

LA JOLLA PHARMACEUTICAL COMPANY
AMENDED AND RESTATED
2013 EQUITY INCENTIVE PLAN

1. DEFINED TERMS

Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms.

2. PURPOSE

The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Awards.

3. ADMINISTRATION

The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; prescribe forms, rules and procedures; and otherwise do all things necessary to carry out the purposes of the Plan. In the case of any Award intended to be eligible for the performance-based compensation exception under Section 162(m), the Administrator will exercise its discretion consistent with qualifying the Award for that exception. Determinations of the Administrator made under the Plan will be conclusive and will bind all parties.

4. LIMITS ON AWARDS UNDER THE PLAN

(a) Number of Shares. The maximum number of shares of Stock that may be delivered upon satisfaction of Awards under the Plan shall be 8,100,000 shares of Stock (the “Reserve”). The limits set forth in this Section 4(a) shall be construed to comply with Section 422. Without limiting the generality of the foregoing, no more than 8,100,000 shares of Stock may be issued in satisfaction of the exercise or surrender of ISOs granted under the Plan. To the extent consistent with the requirements of Section 422 and with other applicable legal requirements (including applicable stock exchange requirements), Stock issued under awards of an acquired company that are converted, replaced, or adjusted in connection with the acquisition shall not reduce the number of shares available for Awards under the Plan.

(b) Type of Shares. Stock delivered by the Company under the Plan may be authorized but unissued Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan.

(c) Section 162(m) Limits. The maximum number of shares subject to Awards that may be granted to any person in any calendar year and the maximum number of shares of Stock subject to SARs granted to any person in any calendar year will each be equal to 500,000 shares of Stock, provided that such limit is established solely for 162(m) purposes and that the excess portion of any award(s) granted above such limit shall not be deductible for purposes of Section 162(m). The maximum amount payable to any person in any year under Cash Awards will be $250,000. The foregoing provisions will be construed in a manner consistent with Section 162(m).

5. ELIGIBILITY AND PARTICIPATION

The Administrator will select Participants from among those key Employees and directors of, and consultants and advisors to, the Company or its Affiliates who, in the opinion of the Administrator, are in a position to make a significant contribution to the success of the Company and its Affiliates; provided, that, subject to such express exceptions, if any, as the Administrator may establish, eligibility shall be further limited to those persons as to whom the use of a Form S-8 registration statement is permissible. Eligibility for ISOs is limited to employees of the Company or of a “parent corporation” or “subsidiary corporation” of the Company as those terms are defined in Section 424 of the Code.lajolla2019proxycard01page1.jpg



6. RULES APPLICABLE TO AWARDSlajolla2019proxycard01page2.jpg

(a) All Awards

(1) Award Provisions. The Administrator will determine the terms of all Awards, subject to the limitations provided herein. By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant agrees to the terms of the Award and the Plan. Notwithstanding any provision of this Plan to the contrary, awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition may contain terms and conditions that are inconsistent with the terms and conditions specified herein, as determined by the Administrator.

(2) Term of Plan. No Awards may be made after September 24, 2023, although previously granted Awards may continue beyond that date in accordance with their terms.

(3) Transferability. Neither ISOs nor, except as the Administrator otherwise expressly provides in accordance with the second sentence of this Section 6(a)(3), other Awards may be transferred other than by will or by the laws of descent and distribution, and during a Participant’s lifetime ISOs (and, except as the Administrator otherwise expressly provides in accordance with the second sentence of this Section 6(a)(3), other Awards requiring exercise) may be exercised only by the Participant. The Administrator may permit Awards, other than ISOs, to be transferred by gift, subject to such limitations as the Administrator may impose.

(4) Vesting, Etc. The Administrator may determine the time or times at which an Award will vest or become exercisable and the terms on which an Award requiring exercise will remain exercisable. Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, regardless of any adverse or potentially adverse tax consequences resulting from such acceleration. Unless the Administrator expressly provides otherwise, however, the following rules will apply:

(A) Immediately upon the cessation of the Participant’s Employment and except as provided in (B) and (C) below, each Award requiring exercise that is then held by the Participant or by the Participant’s permitted transferees, if any, will cease to be exercisable and will terminate, and all other Awards that are then held by the Participant or by the Participant’s permitted transferees, if any, to the extent not already vested will be forfeited.

(B) Subject to (C) and (D) below, all Stock Options and SARs held by the Participant or the Participant’s permitted transferees, if any, immediately prior to the cessation of the Participant’s Employment, to the extent then exercisable, will remain exercisable for the lesser of (i) a period of three months or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon terminate.

(C) All Stock Options and SARs held by a Participant or the Participant’s permitted transferees, if any, immediately prior to the Participant’s death, to the extent then exercisable, will remain exercisable for the lesser of (i) the one year period ending with the first anniversary of the Participant’s death or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon terminate.

(D) All Stock Options and SARs held by a Participant or the Participant’s permitted transferees, if any, immediately prior to the cessation of the Participant’s Employment will immediately terminate upon such cessation of Employment if the Administrator, in its sole discretion, determines that such cessation of Employment has resulted for reasons which cast such discredit on the Participant as to justify immediate termination of the Award.

(5) Taxes. The delivery, vesting or retention of Stock under an Award is conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the Award. The Administrator will prescribe such rules for the withholding of taxes as it deems necessary. The Administrator may, but need not, hold back shares of Stock from an Award or permit a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements (but not in excess of the minimum withholding required by law).

(6) Dividend Equivalents, Etc. The Administrator may provide for the payment of amounts in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award. Any entitlement to dividend equivalents or similar entitlements shall be established and administered consistent either with exemption from, or compliance with, the requirements of Section 409A.



(7) Rights Limited. Nothing in the Plan will be construed as giving any person the right to continued employment or service with the Company or its Affiliates, or any rights as a shareholder except as to shares of Stock actually issued under the Plan. The loss of existing or potential profit in Awards will not constitute an element of damages in the event of termination of Employment for any reason, even if the termination is in violation of an obligation of the Company or any Affiliate to the Participant.

(8) Section 162(m). This Section 6(a)(8) applies to any Performance Award intended to qualify as performance-based for the purposes of Section 162(m) other than a Stock Option or SAR. In the case of any Performance Award to which this Section 6(a)(8) applies, the Plan and such Award will be construed to the maximum extent permitted by law in a manner consistent with qualifying the Award for such exception. With respect to such Performance Awards, the Administrator will pre-establish, in writing, one or more specific Performance Criteria no later than 90 days after the commencement of the period of service to which the performance relates (or at such earlier time as is required to qualify the Award as performance-based under Section 162(m)). Prior to grant, vesting or payment of the Performance Award, as the case may be, the Administrator will certify whether the applicable Performance Criteria have been attained and such determination will be final and conclusive. No Performance Award to which this Section 6(a)(8) applies may be granted after the first meeting of the shareholders of the Company held in the fifth year following the year in which the shareholders last approved the list of possible performance measures specified in the definition of “Performance Criteria” until the listed performance measures set forth in the definition of “Performance Criteria” (as originally approved or as subsequently amended) have been resubmitted to and reapproved by the shareholders of the Company in accordance with the requirements of Section 162(m) of the Code, unless such grant is made contingent upon such approval.

(9) Coordination with Other Plans. Awards under the Plan may be granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or its Affiliates. For example, but without limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or its Affiliates may be settled in Stock (including, without limitation, Unrestricted Stock) if the Administrator so determines, in which case the shares delivered shall be treated as awarded under the Plan (and shall reduce the number of shares thereafter available under the Plan in accordance with the rules set forth in Section 4). In any case where an award is made under another plan or program of the Company or its Affiliates and such award is intended to qualify for the performance-based compensation exception under Section 162(m), and such award is settled by the delivery of Stock or another Award under the Plan, the applicable Section 162(m) limitations under both the other plan or program and under the Plan shall be applied to the Plan as necessary (as determined by the Administrator) to preserve the availability of the Section 162(m) performance-based compensation exception with respect thereto.

(10) Section 409A. Each Award shall contain such terms as the Administrator determines, and shall be construed and administered, such that the Award either (i) qualifies for an exemption from the requirements of Section 409A, or (ii) satisfies such requirements.

(11) Certain Requirements of Corporate Law. Awards shall be granted and administered consistent with the requirements of applicable California law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case, as determined by the Administrator.

(b) Awards Requiring Exercise

(1) Time And Manner Of Exercise. Unless the Administrator expressly provides otherwise, an Award requiring exercise by the holder will not be deemed to have been exercised until the Administrator receives a notice of exercise (in form acceptable to the Administrator), which may be an electronic notice, signed (including electronic signature in form acceptable to the Administrator) by the appropriate person and accompanied by any payment required under the Award. If the Award is exercised by any person other than the Participant, the Administrator may require satisfactory evidence that the person exercising the Award has the right to do so.

(2) Exercise Price. The exercise price (or the base value from which appreciation is to be measured) of each Award requiring exercise shall be 100% (in the case of an ISO granted to a ten-percent shareholder within the meaning of subsection (b)(6) of Section 422, 110%) of the fair market value of the Stock subject to the Award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant. To the extent the Company has a class of securities listed for trading on the NASDAQ Stock Market, no Award, once granted, may be re-priced other than in accordance with the applicable shareholder approval requirements of NASDAQ. Fair market value shall be determined by the Administrator consistent with the applicable requirements of Section 422 and Section 409A.



(3) Payment Of Exercise Price. Where the exercise of an Award is to be accompanied by payment, payment of the exercise price shall be by cash or check acceptable to the Administrator, or, if so permitted by the Administrator and if legally permissible, (i) through the delivery of unrestricted shares of Stock that have a fair market value equal to the exercise price, subject to such minimum holding period requirements, if any, as the Administrator may prescribe, (ii) through a broker-assisted exercise program acceptable to the Administrator, (iii) by other means acceptable to the Administrator, or (iv) by any combination of the foregoing permissible forms of payment. The delivery of shares in payment of the exercise price under clause (i) above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe.

(4) Maximum Term. Awards requiring exercise will have a maximum term not to exceed ten (10) years from the date of grant (five (5) years from the date of grant in the case of an ISO granted to a ten-percent shareholder described in Section 6(b)(2)).

7. EFFECT OF CERTAIN TRANSACTIONS

(a) Mergers, etc. Except as otherwise provided in an Award, the following provisions shall apply in the event of a Covered Transaction:

(1) Assumption or Substitution. If the Covered Transaction is one in which there is an acquiring or surviving entity, the Administrator may provide for the assumption of some or all outstanding Awards or for the grant of new awards in substitution therefor by the acquiror or survivor or an affiliate of the acquiror or survivor.

(2) Cash-Out of Awards. If the Covered Transaction is one in which holders of Stock will receive a payment (whether cash, non-cash or a combination of the foregoing) upon consummation, then subject to Section 7(a)(5) the Administrator may provide for payment (a “cash-out”), with respect to some or all Awards or any portion thereof, equal in the case of each affected Award or portion thereof to the excess, if any, of (A) the fair market value of one share of Stock (as determined by the Administrator in its reasonable discretion) times the number of shares of Stock subject to the Award or such portion, over (B) the aggregate exercise or purchase price, if any, under the Award or such portion (in the case of an SAR, the aggregate base value above which appreciation is measured), in each case on such payment terms (which need not be the same as the terms of payment to holders of Stock) and other terms, and subject to such conditions, as the Administrator determines; provided, that the Administrator shall not exercise its discretion under this Section 7(a)(2) with respect to an Award or portion thereof providing for “nonqualified deferred compensation” subject to Section 409A in a manner that would constitute an extension or acceleration of, or other change in, payment terms if such change would be inconsistent with the applicable requirements of Section 409A.

(3) Other Actions. If the Covered Transaction (whether or not there is an acquiring or surviving entity) is one in which there is no assumption, substitution or cash-out, all outstanding Awards requiring exercise will cease to be exercisable and all Awards providing for the future delivery of Stock (including Stock Units and Performance Awards to the extent consisting of Stock Units) shall expire, in each case after such payment or other consideration, if any, as the Administrator deems equitable in the circumstances, as of the effective time of the Covered Transaction.

(4) Termination of Awards Upon Consummation of Covered Transaction. Each Award will terminate upon consummation of the Covered Transaction, other than the following: (i) Awards assumed pursuant to Section 7(a)(1) above; (ii) Awards converted pursuant to the proviso in Section 7(a)(3) into an ongoing right to receive payment other than Stock; and (iii) outstanding shares of Restricted Stock (which shall be treated in the same manner as other shares of Stock, subject to Section 7(a)(5)).

(5) Additional Limitations. Any share of Stock, cash or other property delivered pursuant to Section 7(a)(2) or Section 7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if any, as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction. For purposes of the immediately preceding sentence, a cash-out under Section 7(a)(2) above or the acceleration of exercisability of an Award under Section 7(a)(3) above shall not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other vesting condition. In the case of Restricted Stock that does not vest in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan.



(b) Changes in and Distributions With Respect to Stock

(1) Basic Adjustment Provisions. In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in the Company’s capital structure, the Administrator shall make appropriate adjustments to the maximum number of shares specified in Section 4(a) that may be delivered under the Plan and to the maximum share limits described in Section 4(c), and shall also make appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise prices relating to Awards and any other provision of Awards affected by such change.

(2) Certain Other Adjustments. The Administrator may also make adjustments of the type described in Section 7(b)(1) to take into account distributions to shareholders other than those provided for in Section 7(a) and Section 7(b)(1), or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan and to preserve the value of Awards made hereunder, having due regard for the qualification of ISOs under Section 422, the requirements of Section 409A, and for the performance-based compensation rules of Section 162(m), where applicable.

(3) Continuing Application of Plan Terms. References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section 7.

8. LEGAL CONDITIONS ON DELIVERY OF STOCK

The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until: (i) the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved; (ii) if the outstanding Stock is, at the time of delivery, listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii) all conditions of the Award have been satisfied or waived. If the sale of Stock has not been registered under the Securities Act of 1933, as amended, the Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of such Act. The Company may require that certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending lapse of the applicable restrictions.

9. AMENDMENT AND TERMINATION

The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards; provided, that except as otherwise expressly provided in the Plan, the Administrator may not, without the Participant’s consent, alter the terms of an Award so as to affect materially and adversely the Participant’s rights under the Award, unless the Administrator expressly reserved the right to do so at the time of the Award. Any amendments to the Plan shall be conditioned upon shareholder approval only to the extent, if any, such approval is required by law (including the Code and applicable stock exchange requirements), as determined by the Administrator.

10. OTHER COMPENSATION ARRANGEMENTS

The existence of the Plan or the grant of any Award will not in any way affect the Company’s right to award a person bonuses or other compensation in addition to Awards under the Plan.

11. MISCELLANEOUS

(a) Waiver of Jury Trial. By accepting an Award under the Plan, each Participant waives any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees that any such action, proceedings or counterclaim shall be tried before a court and not before a jury. By accepting an Award under the Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers.



(b) Limitation of Liability. Notwithstanding anything to the contrary in the Plan, neither the Company, nor any Affiliate, nor the Administrator, nor any person acting on behalf of the Company, any Affiliate, or the Administrator, shall be liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of an Award by reason of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Section 422 or Section 409A or by reason of Section 4999 of the Code, or otherwise asserted with respect to the Award; provided, that nothing in this Section 11(b) shall limit the ability of the Administrator or the Company, in its discretion, to provide by separate express written agreement with a Participant for a gross-up payment or other payment in connection with any such acceleration of income or additional tax.

12. ESTABLISHMENT OF SUB-PLANS

The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board will establish such sub-plans by adopting supplements to the Plan setting forth (i) such limitations on the Administrator’s discretion under the Plan as the Board deems necessary or desirable and (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board deems necessary or desirable. All supplements adopted by the Board will be deemed to be part of the Plan, but each supplement will apply only to Participants within the affected jurisdiction and the Company will not be required to provide copies of any supplement to Participants in any jurisdiction that is not affected.

13. GOVERNING LAW

Except as otherwise provided by the express terms of an Award agreement or under a sub-plan described in Section 12, the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of our based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.



EXHIBIT A
Definition of Terms

The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below:

“Administrator”: The Board, except that the Board may delegate (i) to one or more of its members (or one or more other members of the Board) such of its duties, powers and responsibilities as it may determine; and (ii) to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. In the event of any delegation described in the preceding sentence, the term “Administrator” shall include the person or persons so delegated to the extent of such delegation.

“Affiliate”: Any corporation or other entity that stands in a relationship to the Company that would result in the Company and such corporation or other entity being treated as one employer under Section 414(b) and Section 414(c) of the Code.

“Award”: Any or a combination of the following:
(i) Stock Options.
(ii) SARs.
(iii) Restricted Stock.
(iv) Unrestricted Stock.
(v) Stock Units, including Restricted Stock Units.
(vi) Performance Awards.
(vii) Cash Awards.
(viii) Awards (other than Awards described in (i) through (vii) above) that are convertible into or otherwise based on Stock.

“Board”: The Board of Directors of the Company.

“Cash Award”: An Award denominated in cash.

“Code”: The U.S. Internal Revenue Code of 1986 as from time to time amended and in effect, or any successor statute as from time to time in effect.

“Company”: La Jolla Pharmaceutical Company, a California corporation.

“Covered Transaction”: Any of (i) a consolidation, merger, or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company’s then outstanding Common Stock by a single person or entity or by a group of persons and/or entities acting in concert, (ii) a sale or transfer of all or substantially all the Company’s assets, or (iii) a dissolution or liquidation of the Company. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction shall be deemed to have occurred upon consummation of the tender offer.

“Employee”: Any person who is employed by the Company or an Affiliate.



“Employment”: A Participant’s employment or other service relationship with the Company and its Affiliates. Employment will be deemed to continue, unless the Administrator expressly provides otherwise, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section 5 to the Company or its Affiliates. If a Participant’s employment or other service relationship is with an Affiliate and that entity ceases to be an Affiliate, the Participant’s Employment will be deemed to have terminated when the entity ceases to be an Affiliate unless the Participant transfers Employment to the Company or its remaining Affiliates. Notwithstanding the foregoing and the definition of “Affiliate” above, in construing the provisions of any Award relating to the payment of “nonqualified deferred compensation” (subject to Section 409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms shall be construed to require a “separation from service” (as that term is defined in Section 1.409A-1(h) of the Treasury Regulations) from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single “service recipient” with the Company under Section 1.409A-1(h)(3) of the Treasury Regulations. The Company may, but need not, elect in writing, subject to the applicable limitations under Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a “separation from service” has occurred. Any such written election shall be deemed a part of the Plan.

“ISO”: A Stock Option intended to be an “incentive stock option” within the meaning of Section 422. Each option granted pursuant to the Plan will be treated as providing by its terms that it is to be a non-incentive stock option unless, as of the date of grant, it is expressly designated as an ISO.

“Participant”: A person who is granted an Award under the Plan.

“Performance Award”: An Award subject to Performance Criteria. The Committee in its discretion may grant Performance Awards that are intended to qualify for the performance-based compensation exception under Section 162(m) and Performance Awards that are not intended so to qualify.

“Performance Criteria”: Specified criteria, other than the mere continuation of Employment or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. For purposes of Awards that are intended to qualify for the performance-based compensation exception under Section 162(m), a Performance Criterion will mean an objectively determinable measure of performance relating to any or any combination of the following (measured either absolutely or by reference to an index or indices and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof): sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; stock price; shareholder return; operating or gross margin; operating income; net income (before or after taxes); net operating income; net operating income after tax; pre-and after-tax income; pre-tax profit; cash flow (determined in the aggregate or on a per share basis); operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of expense or working capital levels; economic value added (or an equivalent metric); debt reduction; implementation or completion of projects or processes; sales of particular products or services; customer acquisition, retention or satisfaction; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, split-ups and the like; reorganizations; or recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings. A Performance Criterion and any targets with respect thereto determined by the Administrator need not be based upon an increase, a positive or improved result or avoidance of loss. To the extent consistent with the requirements for satisfying the performance-based compensation exception under Section 162(m), the Administrator may provide in the case of any Award intended to qualify for such exception that one or more of the Performance Criteria applicable to such Award will be adjusted in an objectively determinable manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria.

“Plan”: La Jolla Pharmaceutical Company 2013 Equity Incentive Plan as from time to time amended and in effect.

“Restricted Stock”: Stock subject to restrictions requiring that it be redelivered or offered for sale to the Company if specified conditions are not satisfied.

“Restricted Stock Unit”: A Stock Unit that is, or as to which the delivery of Stock or cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions.



“SAR”: A right entitling the holder upon exercise to receive an amount (payable in cash or in shares of Stock of equivalent value) equal to the excess of the fair market value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured.

“Section 409A”: Section 409A of the Code.

“Section 422”: Section 422 of the Code.

“Section 162(m)”: Section 162(m) of the Code.

“Stock”: Common Stock of the Company, par value $0.001 per share.

“Stock Option”: An option entitling the holder to acquire shares of Stock upon payment of the exercise price.

“Stock Unit”: An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash measured by the value of Stock in the future.

“Unrestricted Stock”: Stock not subject to any restrictions under the terms of the Award.



*            *             *


lajolla2018proxycard001.jpg



lajolla2018proxycard002.jpg